<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5372523</article-id><article-id pub-id-type="doi">10.3390/ijms18030507</article-id><article-id pub-id-type="publisher-id">ijms-18-00507</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Retamales-Ortega</surname><given-names>Roc&#x000ed;o</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref></contrib><contrib contrib-type="author"><name><surname>Or&#x000f3;stica</surname><given-names>Lorena</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref></contrib><contrib contrib-type="author"><name><surname>Vera</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref></contrib><contrib contrib-type="author"><name><surname>Cuevas</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref></contrib><contrib contrib-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref></contrib><contrib contrib-type="author"><name><surname>Hurtado</surname><given-names>Iv&#x000e1;n</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref></contrib><contrib contrib-type="author"><name><surname>Vega</surname><given-names>Margarita</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref><xref ref-type="aff" rid="af2-ijms-18-00507">2</xref></contrib><contrib contrib-type="author"><name><surname>Romero</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00507">1</xref><xref ref-type="aff" rid="af2-ijms-18-00507">2</xref><xref ref-type="aff" rid="af3-ijms-18-00507">3</xref><xref rid="c1-ijms-18-00507" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Fahnestock</surname><given-names>Margaret</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Martinowich</surname><given-names>Keri</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-18-00507"><label>1</label>Laboratory of Endocrinology and Reproductive Biology, Clinical Hospital University of Chile, Santiago 8380456, Chile; <email>rmretama@gmail.com</email> (R.R.-O.); <email>lorenaorostica@gmail.com</email> (L.O.); <email>carolinavera@ug.uchile.cl</email> (C.V.); <email>paucuevasl.2008@gmail.com</email> (P.C.); <email>andrea.gx24@gmail.com</email> (A.H.); <email>ihurtado@hcuch.cl</email> (I.H.); <email>mvega@hcuch.cl</email> (M.V.)</aff><aff id="af2-ijms-18-00507"><label>2</label>Department of Obstetrics and Gynecology, Clinical Hospital, Faculty of Medicine, University of Chile, Santiago 8380456, Chile</aff><aff id="af3-ijms-18-00507"><label>3</label>Advanced Center for Chronic Diseases (ACCDiS), Santiago 8380456, Chile</aff><author-notes><corresp id="c1-ijms-18-00507"><label>*</label>Correspondence: <email>cromero@hcuch.cl</email>; Tel.: +56-2-978-8460</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2017</year></pub-date><volume>18</volume><issue>3</issue><elocation-id>507</elocation-id><history><date date-type="received"><day>28</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Ovarian cancer is the eighth most common cancer in women worldwide, and epithelial ovarian cancer (EOC) represents 90% of cases. Nerve growth factor (NGF) and its high affinity receptor tyrosine kinase A receptor (TRKA) have been associated with the development of several types of cancer, including EOC; both NGF and TRKA levels are elevated in this pathology. EOC presents high angiogenesis and several molecules have been reported to induce this process. NGF increases angiogenesis through its TRKA receptor on endothelial cells, and by indirectly inducing vascular endothelial growth factor expression. Other molecules controlled by NGF include ciclooxigenase-2, disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) and calreticulin (CRT), proteins involved in crucial processes needed for EOC progression. These molecules could be modified through microRNA regulation, which could be regulated by NGF. MicroRNAs are the widest family of non-coding RNAs; they bind to 3&#x02032;-UTR of mRNAs to inhibit their translation, to deadenilate or to degraded them. In EOC, a deregulation in microRNA expression has been described, including alterations of miR-200 family, cluster-17-92, and miR-23b, among others. Since the NGF-microRNA relationship in pathologies has not been studied, this review proposes that some microRNAs could be associated with NGF/TRKA activation, modifying protein levels needed for EOC progression.</p></abstract><kwd-group><kwd>neurotrophins</kwd><kwd>nerve growth factor (NGF)</kwd><kwd>Tyrosine kinase A receptor (TRKA)</kwd><kwd>epithelial ovarian cancer</kwd><kwd>microRNAs</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-18-00507"><title>1. Introduction</title><p>Ovarian cancer is a deadly disease that causes over 140,000 deaths every year [1]. Given the lack of specific symptoms and the poor efficacy of the currently available treatments, the survival rate remains below 50% overall 5-year [<xref rid="B2-ijms-18-00507" ref-type="bibr">2</xref>]. Nerve growth factor (NGF) and its high affinity receptor, Tyrosine kinase A receptor (TRKA), are overexpressed in ovarian cancer and they have been associated with increased proliferation, survival and angiogenesis [<xref rid="B3-ijms-18-00507" ref-type="bibr">3</xref>].</p><p>NGF, through TRKA activation, can alter the expression of several molecules associated with cancer development and progression [<xref rid="B3-ijms-18-00507" ref-type="bibr">3</xref>]. There is also evidence to suggest that NGF could control the expression of microRNAs (miRs) [4,5]. miRs are small non-coding RNA molecules that downregulate gene expression by acting on mRNAs [<xref rid="B6-ijms-18-00507" ref-type="bibr">6</xref>]. Several miRs have been linked to cancer, either through overexpression or downregulation, altering the levels of oncogenes or tumor suppressor genes [<xref rid="B7-ijms-18-00507" ref-type="bibr">7</xref>].</p><p>In this review, an overview is given about ovarian cancer and its most common form, epithelial ovarian cancer (EOC). A summary of neurotrophins and miRs roles on EOC is also provided. Finally, a potential link between EOC, NGF and miRs is established.</p></sec><sec id="sec2-ijms-18-00507"><title>2. Ovarian Cancer</title><p>Ovarian cancer remains major health problem worldwide, with over 225,000 new cases and 140,000 deaths reported annually [<xref rid="B1-ijms-18-00507" ref-type="bibr">1</xref>]. Symptoms associated with ovarian cancer are often nonspecific [<xref rid="B8-ijms-18-00507" ref-type="bibr">8</xref>]; therefore, the majority of patients are diagnosed at advanced stages of the disease [<xref rid="B9-ijms-18-00507" ref-type="bibr">9</xref>], which increases treatment cost and diminishes survival rate [<xref rid="B10-ijms-18-00507" ref-type="bibr">10</xref>].</p><p>It has been suggested that ovarian cancer is linked to an increased number of menstrual cycles [<xref rid="B11-ijms-18-00507" ref-type="bibr">11</xref>]; early menarche, null parity, late menopause and not taking oral contraceptives are among its risk factors [<xref rid="B12-ijms-18-00507" ref-type="bibr">12</xref>]. Other risk factors include smoking [<xref rid="B13-ijms-18-00507" ref-type="bibr">13</xref>], obesity [<xref rid="B14-ijms-18-00507" ref-type="bibr">14</xref>] and estrogen-based hormone replacement therapy after menopause [<xref rid="B15-ijms-18-00507" ref-type="bibr">15</xref>].</p><p>A dualistic model categorizes ovarian tumors into two groups: type I and type II [16]. Type I tumors are part of a morphological continuum of tumor progression starting with benign tumors that develop into borderline tumors and finally into invasive tumors. These invasive tumors lose their differentiation along with their progression. Type II tumors, on the other hand, are aggressive high-grade, poorly differentiated carcinomas that are usually diagnosed at an advanced stage and have poor prognosis [<xref rid="B16-ijms-18-00507" ref-type="bibr">16</xref>]. Clinically, ovarian cancer is classified according to the International Federation of Gynecology and Obstetrics (FIGO) criteria [17]. According to these guidelines, stage I consists of a tumor that is limited to the ovaries, while stage II tumors have expanded to the peritoneal space. In stage III, the tumor has spread through one or both ovaries, accompanied by primary peritoneal cancer and metastasis to the retroperitoneal lymph nodes. Lastly, stage IV consists of distant metastasis to extra-abdominal organs [<xref rid="B17-ijms-18-00507" ref-type="bibr">17</xref>].</p><p>For ovarian cancer, the 5-year survival rate is low [<xref rid="B2-ijms-18-00507" ref-type="bibr">2</xref>]. Because of the lack of efficient early diagnosis tools, ovarian cancer is mostly diagnosed at advanced stages, as has already been stated. This is unfortunate, given that early detection is the most effective means of reducing ovarian cancer mortality [<xref rid="B18-ijms-18-00507" ref-type="bibr">18</xref>]. For example, currently 25% of ovarian cancer cases are detected at stage I or II [<xref rid="B9-ijms-18-00507" ref-type="bibr">9</xref>]; however, if 75% of ovarian cancer cases were to be detected at an early stage of the disease, the number of deaths would be reduced by 50% [<xref rid="B19-ijms-18-00507" ref-type="bibr">19</xref>]. At present, only 15% of patients are diagnosed when the disease is confined to the ovary at the time of diagnosis [<xref rid="B9-ijms-18-00507" ref-type="bibr">9</xref>]; in most cases, at the time of diagnosis the disease has already spread through the ovary and into the peritoneal space. Under these conditions ovarian cancer responds poorly to therapy and the 5-year survival rate drops to between 17% and 30% [<xref rid="B20-ijms-18-00507" ref-type="bibr">20</xref>]. However, if diagnosed at an early stage, when the disease is restricted to the ovary, about 90% of patients survive 5 years after treatment [<xref rid="B21-ijms-18-00507" ref-type="bibr">21</xref>]. The late diagnosis that characterizes ovarian cancer is in part due to the lack of specific symptoms, which include abdominal pain, fatigue, indigestion, constipation, back pain, menstrual irregularities and changes in appetite [<xref rid="B22-ijms-18-00507" ref-type="bibr">22</xref>].</p><p>The main treatment for ovarian cancer is surgery followed by chemotherapy [<xref rid="B23-ijms-18-00507" ref-type="bibr">23</xref>]. The surgery consists of cytoreduction in order to remove the tumor, and then chemotherapy is applied to eliminate the remaining tumor mass [<xref rid="B24-ijms-18-00507" ref-type="bibr">24</xref>]. First line chemotherapy involves the use of platinum-based therapy, including cisplatin and carboplatin, with an adjuvant therapy like paclitaxel [<xref rid="B25-ijms-18-00507" ref-type="bibr">25</xref>]. Around 70% of patients respond to this combination, making ovarian cancer a highly chemotherapy-sensible cancer [<xref rid="B26-ijms-18-00507" ref-type="bibr">26</xref>]. However, approximately 60% of patients develop recurrence, and in these patients the returning tumor is resistant to the first line treatment [<xref rid="B27-ijms-18-00507" ref-type="bibr">27</xref>]. Second- and third-line treatments usually do not have a high response rate, decreasing the 5-year survival rate to 27% [<xref rid="B28-ijms-18-00507" ref-type="bibr">28</xref>].</p><p>Because the late diagnosis and poor response to treatment, ovarian cancer ranks among the leading causes of cancer death, being the eighth most common cause of mortality in women due to cancer worldwide [<xref rid="B29-ijms-18-00507" ref-type="bibr">29</xref>]. Even though extensive research has been done in order to better diagnose and treatment for this disease, ovarian carcinoma pathogenesis is not yet completely understood.</p></sec><sec id="sec3-ijms-18-00507"><title>3. Epithelial Ovarian Cancer</title><p>Ovarian cancer consists of a malignant tumor that forms in the ovary. The ovary has three main cell types that can develop into a different type of tumor: germ cells can grow into germ cell tumors [<xref rid="B30-ijms-18-00507" ref-type="bibr">30</xref>], stromal cells give rise to stromal sex cord tumors [<xref rid="B31-ijms-18-00507" ref-type="bibr">31</xref>] and the origin of EOC is from the epithelial cells of the ovary [<xref rid="B32-ijms-18-00507" ref-type="bibr">32</xref>]. Most malignant tumors are of epithelial origin, comprising around 90% of all ovarian cancers [<xref rid="B33-ijms-18-00507" ref-type="bibr">33</xref>].</p><p>About 10% to 20% of EOC cases are of hereditary origin [<xref rid="B34-ijms-18-00507" ref-type="bibr">34</xref>], and mutations of the breast cancer gene 1 (BRCA1) or the breast cancer gene 2 (BRCA2) are the most significant genetic mutations associated with an increase in overall ovarian cancer risk [<xref rid="B35-ijms-18-00507" ref-type="bibr">35</xref>]. EOC is more common in older, postmenauposal women; therefore, this tumor is usually found in inactive ovaries that are no longer undergoing reproductive cycles [<xref rid="B36-ijms-18-00507" ref-type="bibr">36</xref>].</p><p>While it was originally thought that EOC originated from the epithelial cells that can be found on the outer layer of tissue surrounding the inactive ovary or on the surface of ovarian cysts [<xref rid="B32-ijms-18-00507" ref-type="bibr">32</xref>], there are presently several theories relating to the cell origin of EOC. Some investigators propose that EOC could develop from cysts located in the secondary M&#x000fc;llerian system [<xref rid="B37-ijms-18-00507" ref-type="bibr">37</xref>]. According to this theory, the tumor would grow from these cysts and thus appear to have an ovarian origin. Also, recent research suggests that EOC arises at the fallopian epithelium and it spreads to the ovary from there [<xref rid="B38-ijms-18-00507" ref-type="bibr">38</xref>].</p><p>In EOC, just like in any cancer, several signaling pathways are altered, resulting in uncontrolled growth, apoptosis avoidance and the acquisition of invasion capability, among other carcinogenic features [<xref rid="B39-ijms-18-00507" ref-type="bibr">39</xref>]. One of the most studied altered mechanisms in EOC is angiogenesis, a necessary process given the large size that characterizes ovarian tumors [<xref rid="B40-ijms-18-00507" ref-type="bibr">40</xref>]. Vascular endothelial growth factor (VEGF) is an angiogenic factor and potent mitogen for the vascular endothelium [<xref rid="B41-ijms-18-00507" ref-type="bibr">41</xref>] and one of the most important factors in ovarian angiogenesis, both in normal [<xref rid="B42-ijms-18-00507" ref-type="bibr">42</xref>] and in pathological tissues [<xref rid="B43-ijms-18-00507" ref-type="bibr">43</xref>]. Bevacizumab, a monoclonal antibody targeting VEGF, has shown moderate success in clinical trials against ovarian cancer [<xref rid="B44-ijms-18-00507" ref-type="bibr">44</xref>,<xref rid="B45-ijms-18-00507" ref-type="bibr">45</xref>] and it has been approved in Europe against advanced or recurrent in this disease in combination with other chemotherapy medicines [<xref rid="B46-ijms-18-00507" ref-type="bibr">46</xref>].</p><p>In addition to the importance of angiogenesis in tumor processes, cancer cells are characterized by a lack of cell growth control [<xref rid="B39-ijms-18-00507" ref-type="bibr">39</xref>]. This occurs in part through signaling generated from a variety of growth factor receptors, including the ones belonging to the tyrosine kinase receptor family [<xref rid="B47-ijms-18-00507" ref-type="bibr">47</xref>]. Neurotrophins can interact with these receptors, inducing pro carcinogenic responses [<xref rid="B48-ijms-18-00507" ref-type="bibr">48</xref>].</p></sec><sec id="sec4-ijms-18-00507"><title>4. Neurotrophins and Their Role in Ovarian Cancer</title><p>Neurotrophins are a family of small polypeptides growth factors that consists of five members: NGF, brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), neurotrophin 4/5 (NT-4/5) and neurotrophin 6 (NT-6) [<xref rid="B49-ijms-18-00507" ref-type="bibr">49</xref>]. Neurotrophins act by interacting with two different types of receptors: p75 and the TRK members of the tyrosine kinase receptor superfamily [<xref rid="B50-ijms-18-00507" ref-type="bibr">50</xref>]. The p75 receptor is able to bind all neurotrophins with low affinity [<xref rid="B51-ijms-18-00507" ref-type="bibr">51</xref>], while different TRK receptors bind to a specific neurotrophin with high affinity: NGF binds to TRKA; BDNF and NT4/5 bind to TRKB and NT-3 binds to TRKC, initiating an intracellular signaling response [<xref rid="B52-ijms-18-00507" ref-type="bibr">52</xref>].</p><p>NGF was the first neurotrophin to be described [<xref rid="B53-ijms-18-00507" ref-type="bibr">53</xref>]. It was discovered in the nervous system; however, it has been found to have functions in several other systems, including the cardiovascular [<xref rid="B54-ijms-18-00507" ref-type="bibr">54</xref>], endocrine [<xref rid="B55-ijms-18-00507" ref-type="bibr">55</xref>], immune [<xref rid="B55-ijms-18-00507" ref-type="bibr">55</xref>] and reproductive systems [<xref rid="B56-ijms-18-00507" ref-type="bibr">56</xref>]. Neurotrophins and their receptors are involved in the development and normal functioning of the ovary: NGF plays a role in early follicular development by allowing differentiation of primordial follicles into follicles [<xref rid="B57-ijms-18-00507" ref-type="bibr">57</xref>]. This function is apparently due to NGF&#x02019;s ability to act in granulosa and theca cells and to induce their proliferation [<xref rid="B58-ijms-18-00507" ref-type="bibr">58</xref>,<xref rid="B59-ijms-18-00507" ref-type="bibr">59</xref>]. NGF also participates in ovulation by inducing the release of prostaglandins, a necessary step in the ovulatory molecular cascade [<xref rid="B60-ijms-18-00507" ref-type="bibr">60</xref>]. Besides, NGF is able to induce the expression of Follicle Stimulating Hormone Receptor (FSH-R) and estradiol in human granulosa cells [<xref rid="B61-ijms-18-00507" ref-type="bibr">61</xref>].</p><p>Angiogenesis is a key process during the normal ovarian cycle, due to the need of new blood vessel formation in each ovulatory cycle [<xref rid="B62-ijms-18-00507" ref-type="bibr">62</xref>]. In fact, the ovary is one of the few organs in which angiogenesis occurs in a cyclically controlled manner. During reproductive life, VEGF is one of the most important proangiogenic factors involved in cyclic angiogenesis, by being participant in the periodic growth of follicles and in the development [<xref rid="B63-ijms-18-00507" ref-type="bibr">63</xref>] and maintenance of the corpeus luteus [<xref rid="B64-ijms-18-00507" ref-type="bibr">64</xref>,<xref rid="B65-ijms-18-00507" ref-type="bibr">65</xref>]. This growth factor expression is controlled by several factors, including FSH and Luteinizing Hormone (LH), through their receptors FSHR and LHR, respectively [<xref rid="B66-ijms-18-00507" ref-type="bibr">66</xref>]. Both NGF and TRKA, its high affinity receptor, are expressed in the ovary [3]. Equal to VEGF, TRKA and NGF are expressed before ovulation, suggesting a role of these proteins in ovarian function and angiogenesis [<xref rid="B3-ijms-18-00507" ref-type="bibr">3</xref>]. Interestingly, NGF can induce angiogenesis in endothelial cells [<xref rid="B67-ijms-18-00507" ref-type="bibr">67</xref>]. Besides, NGF is able to induce a neovascularization process in the superior ganglion of newborn rats, which is accompanied by an increase of VEGF production [<xref rid="B68-ijms-18-00507" ref-type="bibr">68</xref>]. In granulosa cell lines, NGF is able to induce VEGF expression through TRKA activation [<xref rid="B69-ijms-18-00507" ref-type="bibr">69</xref>]. These findings suggest that NGF and TRKA are important in the regulation of the normal ovarian function.</p><p>In EOC, angiogenesis, which is tightly controlled during the regular cycle, becomes unregulated [<xref rid="B70-ijms-18-00507" ref-type="bibr">70</xref>]. Because of the normal angiogenesis that occurs on the cyclic ovary during reproductive life, it is possible to suggest that ovarian cells keep their capability for angiogenesis. After malignant transformation, cancer cells could use their advantage of inducing angiogenesis as a mean to acquire nutrients and oxygen. In line with this, both NGF and TRKA have been involved in the angiogenesis of EOC through VEGF induction [71], whose production is the main component of angiogenesis in ovarian cancer [<xref rid="B72-ijms-18-00507" ref-type="bibr">72</xref>] (<xref ref-type="fig" rid="ijms-18-00507-f001">Figure 1</xref>). The VEGF gene encodes five different protein isoforms (VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206) that are generated by alternative splicing from a single gene [73]. While VEGF121 is efficiently secreted from the cell, VEGF165 is partially retained on the cell surface and the other VEGF isoforms are primarily retained on the surface [<xref rid="B73-ijms-18-00507" ref-type="bibr">73</xref>]. In EOC explants, NGF induces an increase of VEGF121, VEGF165 and VEGF189 mRNA levels, as well the amount of VEGF protein secreted from the explants; these actions are mediated by TRKA [<xref rid="B71-ijms-18-00507" ref-type="bibr">71</xref>].</p><p>Neurotrophins have also been involved in other tumorigenic processes besides angiogenesis, including growth deregulation that normally occurs in cancer. Tyrosine kinase receptors are overexpressed in cancer, or have their activity altered [74,75]. As a result, there is an alteration of their intracellular signaling [<xref rid="B76-ijms-18-00507" ref-type="bibr">76</xref>]. NGF and TRKA overexpression has been found in several cancer types, including thyroid [<xref rid="B77-ijms-18-00507" ref-type="bibr">77</xref>], lung [<xref rid="B78-ijms-18-00507" ref-type="bibr">78</xref>], esophagus [<xref rid="B79-ijms-18-00507" ref-type="bibr">79</xref>], prostate [<xref rid="B75-ijms-18-00507" ref-type="bibr">75</xref>], breast [<xref rid="B74-ijms-18-00507" ref-type="bibr">74</xref>] and ovarian cancer [<xref rid="B3-ijms-18-00507" ref-type="bibr">3</xref>]. In ovarian cancer, TRKA and its active form, p-TRKA, are overexpressed [80]. Interestingly, studies either have not found p-TRKA in normal tissues or it has only been found in a small number of samples [<xref rid="B80-ijms-18-00507" ref-type="bibr">80</xref>]. Besides, NGF induces an increase of proliferation molecules and a decrease of apoptosis markers after NGF stimulation in EOC explants [<xref rid="B81-ijms-18-00507" ref-type="bibr">81</xref>] (<xref ref-type="fig" rid="ijms-18-00507-f001">Figure 1</xref>).</p><p>NGF appears to be controlling other molecules involved in EOC tumorigenesis (<xref ref-type="fig" rid="ijms-18-00507-f001">Figure 1</xref>), such as ciclooxigenase-2 [<xref rid="B82-ijms-18-00507" ref-type="bibr">82</xref>] a molecule that participates in inflammation through prostaglandine E2 production [<xref rid="B83-ijms-18-00507" ref-type="bibr">83</xref>]. Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a proteinase involved in metastasis and migration [<xref rid="B84-ijms-18-00507" ref-type="bibr">84</xref>], also seems to be controlled by NGF [<xref rid="B85-ijms-18-00507" ref-type="bibr">85</xref>]. ADAM17 is able to cause TRKA cleavage, facilitating cell survival and proliferation. Besides, upon TRKA activation through NGF binding, ADAM 17 cleaves p75 on its extracellular domain, and afterwards &#x003b3;-secretase cleaves it on the intracellular domain [<xref rid="B86-ijms-18-00507" ref-type="bibr">86</xref>]. The biological consequences of these processes are not completely understood. NGF also induces an increase of calreticulin levels [<xref rid="B87-ijms-18-00507" ref-type="bibr">87</xref>], a chaperone that has been associated with survival and migration of cancer cells [<xref rid="B88-ijms-18-00507" ref-type="bibr">88</xref>,<xref rid="B89-ijms-18-00507" ref-type="bibr">89</xref>]. We are currently doing research to further elucidate these and other pathways in which NGF is involved with EOC carcinogenesis.</p><p>The evidence presented above shows that NGF alters the expression of several molecules that are involved in tumorigenic processes in ovarian cancer; however, this deregulation could be through different mechanisms: NGF could act at an epigenetic level, induce DNA mutations, induce chromosomal alterations, and/or alter post-transcriptional or post-translational regulations. Today, one of the most widely studied mechanisms for protein synthesis control is microRNA-dependent post-transcriptional regulation.</p></sec><sec id="sec5-ijms-18-00507"><title>5. microRNAs and Cancer</title><p>miRs are the widest family of non-coding RNAs, their length is ~22 nucleotides and they regulate post-transcriptional mRNAs. In mammals, there have been ~2000 different miRs described, which are conserved in related species [<xref rid="B90-ijms-18-00507" ref-type="bibr">90</xref>,<xref rid="B91-ijms-18-00507" ref-type="bibr">91</xref>]. miRs are synthesized by RNApol II and they are cleaved, in the nucleus and cytoplasm, for their maturation. miR regulation is performed by the RNA-silencing inducing complex (RISC), composed by a multiprotein complex and the mature miR, where the mRNA target can be paired with partial or total complementarity with miR, leading to mRNA degradation, deadenilation or inhibition of its translation [<xref rid="B92-ijms-18-00507" ref-type="bibr">92</xref>,<xref rid="B93-ijms-18-00507" ref-type="bibr">93</xref>].</p><p>miRs have an important role regulating mRNA expression, which reflects on a modification in protein levels. Interestingly, one miR can regulate up to 30 mRNAs and one mRNA can be regulated by several miRs; then, an alteration of miR expression can regulate several processes. A deregulation of miR expression has been found in several pathologies, including glaucoma, neurodegenerative diseases [<xref rid="B94-ijms-18-00507" ref-type="bibr">94</xref>], cardiovascular pathologies [<xref rid="B95-ijms-18-00507" ref-type="bibr">95</xref>], metabolic diseases [<xref rid="B96-ijms-18-00507" ref-type="bibr">96</xref>] and cancer [<xref rid="B97-ijms-18-00507" ref-type="bibr">97</xref>], among others. Since deregulation in miR expression is crucial for cancer development [<xref rid="B98-ijms-18-00507" ref-type="bibr">98</xref>,<xref rid="B99-ijms-18-00507" ref-type="bibr">99</xref>], the roles of miR in this pathology are divided into two groups: oncomiRs and tumor suppressor miRs [<xref rid="B100-ijms-18-00507" ref-type="bibr">100</xref>]. OncomiRs regulate mRNA of tumor suppressor genes, while tumor suppressor miRs regulate oncogenic gene mRNA expression. OncomiRs are found to be overexpressed, reducing tumor suppressor gene expression, at the same time that tumor suppressor miRs are found to be downregulated, increasing oncogenic gene expression (<xref ref-type="fig" rid="ijms-18-00507-f002">Figure 2</xref>) [<xref rid="B101-ijms-18-00507" ref-type="bibr">101</xref>]. miR expression can be modified in different types of cancer regulating the same mRNAs and producing equal effects in neoplastic transformation. This is a very interesting phenomenon, since different types of cancer could have similar targets that could initiate tumorigenic development [<xref rid="B99-ijms-18-00507" ref-type="bibr">99</xref>].</p><p>Studies have been done in order to find a miR expression pattern in diverse types of cancer, which is being undertaken both in tissue samples, and in samples that require less invasive methods of extraction, like blood and serum [<xref rid="B102-ijms-18-00507" ref-type="bibr">102</xref>]. Even though there is no consensus about miR expression patterns yet [<xref rid="B103-ijms-18-00507" ref-type="bibr">103</xref>], some of those that are being studied are breast [<xref rid="B104-ijms-18-00507" ref-type="bibr">104</xref>], ovarian [<xref rid="B105-ijms-18-00507" ref-type="bibr">105</xref>], esophageal [<xref rid="B106-ijms-18-00507" ref-type="bibr">106</xref>], renal [<xref rid="B107-ijms-18-00507" ref-type="bibr">107</xref>] and bladder [<xref rid="B108-ijms-18-00507" ref-type="bibr">108</xref>] cancers. In ovarian cancer [<xref rid="B109-ijms-18-00507" ref-type="bibr">109</xref>], miRs could potentially be used as reliable markers for diagnosis, prognosis [<xref rid="B110-ijms-18-00507" ref-type="bibr">110</xref>] and even as therapeutic targets [<xref rid="B111-ijms-18-00507" ref-type="bibr">111</xref>].</p></sec><sec id="sec6-ijms-18-00507"><title>6. Role of miRs in Ovarian Cancer</title><p>Several studies have been performed in order to evaluate the role of miRs in ovarian cancer; however, this information has not yet been used with a clinical approach. Some miRs that have been found altered in ovarian cancer include Let-7, miR-200 family, miR-17-92, miR-21, miR-145 and miR-23b [<xref rid="B112-ijms-18-00507" ref-type="bibr">112</xref>,<xref rid="B113-ijms-18-00507" ref-type="bibr">113</xref>,<xref rid="B114-ijms-18-00507" ref-type="bibr">114</xref>]. Most of them have also been studied in other types of cancer, and they can have different roles depending on the cancer type.</p><p>In ovarian cancer, Let-7 is a family of tumor suppressor miR, inhibiting a downstream component of the EGFR signaling network (KRAS), regulating cancer-cell proliferation [<xref rid="B115-ijms-18-00507" ref-type="bibr">115</xref>], protein that belongs to the non-histone chromosomal high-mobility group (HMGA2) associated with both malignant and benign tumor formation, as well as certain characteristic cancer-promoting mutations [<xref rid="B116-ijms-18-00507" ref-type="bibr">116</xref>] and c-Myc [<xref rid="B117-ijms-18-00507" ref-type="bibr">117</xref>]; then Let-7 has been identified as a potential maker for early diagnosis [<xref rid="B118-ijms-18-00507" ref-type="bibr">118</xref>]. Concerning miR-200 family, it has been reported that miR-200c inhibits protein Zinc finger E-box-binding homeobox 1 (ZEB-1) and miR-200a inhibits ZEB-2 [<xref rid="B119-ijms-18-00507" ref-type="bibr">119</xref>], proteins that are important transcription factors that allow epithelial&#x02013;mesenquimal transition and associated with tumor progression. miR-141 inhibits Keap-1 [<xref rid="B120-ijms-18-00507" ref-type="bibr">120</xref>] and miR-200c can regulate B-tubulin III expression [<xref rid="B121-ijms-18-00507" ref-type="bibr">121</xref>]. Finally, if miR-200c levels are restored, there is an increase in overall free progression and survival, and it sensitizes cancer cells to cisplatin and paclitaxel therapies [<xref rid="B122-ijms-18-00507" ref-type="bibr">122</xref>]. The miR-17-92 cluster, an oncomiR, presents a high frequency of genomic alterations [<xref rid="B123-ijms-18-00507" ref-type="bibr">123</xref>] and it induces angiogenesis through inhibition of thrombospondin 1 [<xref rid="B124-ijms-18-00507" ref-type="bibr">124</xref>]. miR-21, an oncomir, regulates Phosphatase and tensin homolog (PTEN), this enzyme acts as a tumor suppressor [<xref rid="B125-ijms-18-00507" ref-type="bibr">125</xref>], it has an inverse relation with programmed cell death protein 4 (PDCD4) expression [<xref rid="B126-ijms-18-00507" ref-type="bibr">126</xref>] and it exerts an inhibitory effect on cancer cell proliferation [<xref rid="B127-ijms-18-00507" ref-type="bibr">127</xref>]. This miR has also been associated with recurrence-free survival, which will be lower if miR-21 levels are elevated [<xref rid="B128-ijms-18-00507" ref-type="bibr">128</xref>]. miR-145 belongs to the miR143/145 cluster [<xref rid="B129-ijms-18-00507" ref-type="bibr">129</xref>]; both miRs have been described as tumor suppressor miRs, and it has been proposed that the downregulation of miR-145 could be used as a predictive value for cancer. miR-145 has been implicated in angiogenesis, decreasing molecules that stimulate this process, like p79S6K1, which regulates hipoxic inducing factor-1a, an important growth factor that stimulates VEGF production, and also regulates directly to VEGF expression [<xref rid="B130-ijms-18-00507" ref-type="bibr">130</xref>]. miR-145 also inhibits c-Myc [<xref rid="B131-ijms-18-00507" ref-type="bibr">131</xref>], decreasing proliferation and inducing apoptosis. Most studies about miR-145 are focused on miR-145-5p, which is defined as the mature strand, while miR-145-3p is the passenger strand. Interestingly, it has recently been reported that both of these miRs could have biological activity, and it is very rare to find duplex miRs where both strands have biological functions [<xref rid="B132-ijms-18-00507" ref-type="bibr">132</xref>]. miR-23b belongs to the miR-23b/27b/24 cluster, it has been described as a tumor suppressor, and some miR-23b targets include cyclin G1 [<xref rid="B133-ijms-18-00507" ref-type="bibr">133</xref>] and the transcription factor RUNX2, involved in cellular survival, migration and invasion [<xref rid="B134-ijms-18-00507" ref-type="bibr">134</xref>]. In ovarian cancer patients, miR-23b has been found to be downregulated and it has been associated with advanced tumor progression and poor prognosis [<xref rid="B133-ijms-18-00507" ref-type="bibr">133</xref>].</p></sec><sec id="sec7-ijms-18-00507"><title>7. NGF and miRs in Ovarian Cancer</title><p>NGF and miR roles in ovarian cancer are well described above, but NGF&#x02019;s role in miR expression in ovarian cancer is far from well understood. There are some studies regarding miR alteration due to neutrophin action. For example, it was reported that miR-204 upregulation downregulates BDNF in order to enhance anoikis in EOC [<xref rid="B135-ijms-18-00507" ref-type="bibr">135</xref>]. With respect to the action of NGF, most of these studies have not been done in EOC or even in cancer; but on neuronal models. What has been reported? Firstly, NGF signaling through ERK protein increases miR-222 and miR-221 levels [<xref rid="B4-ijms-18-00507" ref-type="bibr">4</xref>]; secondly, NGF overexpresses miR-221 levels, with consequences in neuronal differentiation [<xref rid="B5-ijms-18-00507" ref-type="bibr">5</xref>]; thirdly, NGF raises miR-21 levels, supporting its signaling and protecting cells from neuronal degeneration [<xref rid="B136-ijms-18-00507" ref-type="bibr">136</xref>]. While all of these studies have been done on a PC12 cell line, there are also a couple of reports done in bladder [<xref rid="B137-ijms-18-00507" ref-type="bibr">137</xref>] and bronchial epithelium [<xref rid="B138-ijms-18-00507" ref-type="bibr">138</xref>].</p><p>In relation to the signaling pathways that could be involved in NGF-dependent miR expression levels, it has been reported that NGF can stimulate AKT and MAPK phosphorylation in an miR-21-dependent manner, increasing VEGF levels (which are raised with NGF stimulation in EOC). Therefore, miR-21 can be considered as a positive regulator of this neurothrophin signaling [<xref rid="B136-ijms-18-00507" ref-type="bibr">136</xref>]. On the other hand, NGF can function as a positive regulator by increasing miR-221/222 through the activation of the ERK1/2 signaling pathway [<xref rid="B4-ijms-18-00507" ref-type="bibr">4</xref>]. Another important protein for EOC metastasis is ADAM17, which is regulated by a metalloproteinase inhibitor (TIMP3). miR-222 targets TIMP3, decreasing its levels and allowing ADAM17 expression [<xref rid="B139-ijms-18-00507" ref-type="bibr">139</xref>]. Ciclooxigenase-2 (COX-2), an important protein up-regulated in EOC, is regulated by miR-143 [<xref rid="B140-ijms-18-00507" ref-type="bibr">140</xref>]. It has been published that this miR is downregulated in EOC [<xref rid="B141-ijms-18-00507" ref-type="bibr">141</xref>]; besides, it decreases with NGF stimulation in a cellular line derived from a pheochromocytoma of the rat adrenal medulla (PC12) [<xref rid="B5-ijms-18-00507" ref-type="bibr">5</xref>]. Therefore, a NGF-dependent decrease of miR-143 could increase COX-2 levels in EOC.</p><p>We are currently studying the downregulation of miR-23b in EOC [<xref rid="B133-ijms-18-00507" ref-type="bibr">133</xref>]. As mentioned above, this downregulation coincides with the overexpression of NGF. miR-23b has several validated targets, some of which are shown in <xref ref-type="table" rid="ijms-18-00507-t001">Table 1</xref>. The table focuses on those that are involved in different processes associated with EOC, NGF or both. miR-23b target genes related with NGF and EOC include proto-oncogene tyrosine-protein kinase (SRC) and a protein that is involved in controlling the activation of RAS/MAPK signaling (SOS1) and super oxide dismutase 1 (SOD1). SRC is a protein involved in TRK signal transduction, SOS1 is a guanine nucleotide exchange factor (GEF) that is also related to TRK transduction, and finally SOD1 is an enzyme that is in charge of converting superoxide radical into hydrogen peroxide, which could enhance DNA damage.</p><p>The evidence presented above leads us to hypothesize that NGF could be regulating miR-23b downregulation, which is an important step for EOC development. To date, as shown in <xref ref-type="fig" rid="ijms-18-00507-f003">Figure 3</xref>, our results have indicated that miR-23b is downregulated during ovarian cancer progression: in tumor and cancer tissue samples miR-23b levels are lower when compared to inactive ovarian tissue samples (<xref ref-type="fig" rid="ijms-18-00507-f003">Figure 3</xref>A, <italic>p</italic> &#x0003c; 0.01). A comparison between basal conditions of A2780 cells (epithelial ovarian cancer cell line) and HOSE cells (epithelial cells from human inactive ovary) show that miR-23b levels are lower in the A2780 cell line (<xref ref-type="fig" rid="ijms-18-00507-f003">Figure 3</xref>B, <italic>p</italic> &#x0003c; 0.05), suggesting that the higher expression of NGF and TRKA in A2780 cell line could affect miR-23b levels. When we evaluated NGF effect on miR-23b expression in both cell lines, we found that stimulation of A2780 with NGF reduces miR-23b levels (<xref ref-type="fig" rid="ijms-18-00507-f003">Figure 3</xref>C, <italic>p</italic> &#x0003c; 0.05), and in HOSE cells a similar effect was found (<xref ref-type="fig" rid="ijms-18-00507-f003">Figure 3</xref>D, <italic>p</italic> &#x0003c; 0.05). Summarizing, these results show that: (a) miR-23b levels are down-regulated in ovarian cancer, as has been reported; and (b) NGF reduces miR-23b levels in HOSE and A2780 cell lines.</p><p>The next step is to evaluate which proteins regulated by miR-23b in EOC could be enhancing carcinogenic processes in EOC, and if NGF is regulating expression of these proteins. One example of a miR-23b target and its contribution to EOC development is SRC, an oncogene deregulated in several solid tumors, including ovarian cancer. It is a serine/threonine kinase that activates three signaling pathways: STAT3/MYC, MAPKs and PI3K. While SRC is inactive in normal tissues (when miR-23b presents higher levels), it can be activated and overexpressed in cancer cells, inducing carcinogenic processes such as angiogenesis, proliferation, invasion, motility and chemoresistance. SRC has been found to be elevated in some serous EOC patients, making it a possible therapeutic target [<xref rid="B142-ijms-18-00507" ref-type="bibr">142</xref>]. Another example of a mR-23b target is SOS1, which participates in cell migration, a process that requires the participation of proteins from the Rho-GTPase family, including Rac. Rac activity is regulated by Ras through SOS1, and it is responsible for the reorganization of actin cytoskeleton, a necessary process for cell migration. Besides, in ovarian cancer patients, the expression of proteins involved in epithermal growth factor receptor (EGFR) such as a tri-complex SOS1 and Epithermal growth factor receptor Pathway Substrate 8 and an adapter protein ABI-1 (SOS1/EPS8/ABI1) This complex is correlated with advanced clinical stage. In addition, this complex is only present in metastatic ovarian cancer cells, while it is absent in non-metastatic cells [<xref rid="B143-ijms-18-00507" ref-type="bibr">143</xref>]. Another molecule involved in EOC development is the transcription factor c-Myc. This factor increases when ovarian cancer cells are stimulated with NGF [<xref rid="B81-ijms-18-00507" ref-type="bibr">81</xref>]. Interestingly, it is known that c-Myc decreases miR-23b expression in myeloma [<xref rid="B144-ijms-18-00507" ref-type="bibr">144</xref>]. Thus, the negative regulation of miR-23b by c-Myc through NGF could favor EOC progression. The perspectives of these results and analyses are to evaluate the role of NGF in miR-23b regulation in EOC-involved targets.</p></sec><sec id="sec8-ijms-18-00507"><title>8. Conclusions and Perspectives</title><p>NGF is a relevant molecule that stimulates epithelial ovarian cancer cell proliferation, migration, invasion and angiogenesis; processes that are crucial for ovarian cancer development. On the other hand, the post-transcriptional regulation of miRs is altered in several pathologies, including EOC, and this deregulation is involved in different characteristics that initiate neoplastic transformation. With respect to how NGF and miR are involved in EOC progression, it is important to evaluate its relationship in this pathology. NGF could modify some miR levels, oncomiRs and tumor suppressor miRs, in order to increase levels of VEGF, COX2, ADAM17, and other proteins (<xref ref-type="fig" rid="ijms-18-00507-f004">Figure 4</xref>). As reported above, it is known that NGF regulates some miR expression in EOC, but it is necessary to further investigate in order to know which miR could be used as an early diagnosis tool and/or for therapy development.</p></sec></body><back><ack><title>Acknowledgments</title><p>This review was supported by grants #1110372 and #1160139 from Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico, Chile (to CR). Conicyt-Fondap 15130011 (ACCDiS).</p></ack><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">EOC</td><td align="left" valign="middle" rowspan="1" colspan="1">Epithelial ovarian cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Nerve growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular endothelial growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">miR</td><td align="left" valign="middle" rowspan="1" colspan="1">MicroRNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRKA</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyrosine kinase A receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADAM17</td><td align="left" valign="middle" rowspan="1" colspan="1">Disintegrin and metalloproteinase domain-containing protein 17</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-18-00507"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Shin</surname><given-names>H.R.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Forman</surname><given-names>D.</given-names></name><name><surname>Mathers</surname><given-names>C.</given-names></name><name><surname>Parkin</surname><given-names>D.M.</given-names></name></person-group>
<article-title>Estimates of worldwide burden of cancer</article-title>
<source>Int. J. Cancer.</source>
<year>2008</year>
<volume>127</volume>
<fpage>2893</fpage>
<lpage>2917</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.25516</pub-id>
<?supplied-pmid 21351269?><pub-id pub-id-type="pmid">21351269</pub-id></element-citation></ref><ref id="B2-ijms-18-00507"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Ward</surname><given-names>E.</given-names></name><name><surname>Brawley</surname><given-names>O.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group>
<article-title>Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths</article-title>
<source>CA Cancer J. Clin.</source>
<year>2011</year>
<volume>61</volume>
<fpage>212</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.3322/caac.20121</pub-id>
<?supplied-pmid 21685461?><pub-id pub-id-type="pmid">21685461</pub-id></element-citation></ref><ref id="B3-ijms-18-00507"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vera</surname><given-names>C.</given-names></name><name><surname>Tapia</surname><given-names>V.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis</article-title>
<source>J. Ovarian Res.</source>
<year>2014</year>
<volume>7</volume>
<fpage>82</fpage>
<pub-id pub-id-type="doi">10.1186/s13048-014-0082-6</pub-id>
<?supplied-pmid 25296882?><pub-id pub-id-type="pmid">25296882</pub-id></element-citation></ref><ref id="B4-ijms-18-00507"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terasawa</surname><given-names>K.</given-names></name><name><surname>Ichimura</surname><given-names>A.</given-names></name><name><surname>Sato</surname><given-names>F.</given-names></name><name><surname>Shimizu</surname><given-names>K.</given-names></name><name><surname>Tsujimoto</surname><given-names>G.</given-names></name></person-group>
<article-title>Sustained activation ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells</article-title>
<source>FEBS J.</source>
<year>2009</year>
<volume>276</volume>
<fpage>3269</fpage>
<lpage>3276</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07041.x</pub-id>
<?supplied-pmid 19438724?><pub-id pub-id-type="pmid">19438724</pub-id></element-citation></ref><ref id="B5-ijms-18-00507"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamada</surname><given-names>N.</given-names></name><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Kojima</surname><given-names>T.</given-names></name><name><surname>Kitamoto</surname><given-names>A.</given-names></name><name><surname>Akao</surname><given-names>Y.</given-names></name><name><surname>Nozawa</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name></person-group>
<article-title>MicroRNA expression profiling of NGF-treated PC12 cells revealed a critical role for miR-221 in neuronal differentiation</article-title>
<source>Neurochem. Int.</source>
<year>2012</year>
<volume>60</volume>
<fpage>743</fpage>
<lpage>750</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2012.03.010</pub-id>
<?supplied-pmid 22465943?><pub-id pub-id-type="pmid">22465943</pub-id></element-citation></ref><ref id="B6-ijms-18-00507"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruvkun</surname><given-names>G.</given-names></name></person-group>
<article-title>Molecular biology: Glimpses of a tiny RNA world</article-title>
<source>Science</source>
<year>2001</year>
<volume>294</volume>
<fpage>797</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="doi">10.1126/science.1066315</pub-id>
<?supplied-pmid 11679654?><pub-id pub-id-type="pmid">11679654</pub-id></element-citation></ref><ref id="B7-ijms-18-00507"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jansson</surname><given-names>M.D.</given-names></name><name><surname>Lund</surname><given-names>A.H.</given-names></name></person-group>
<article-title>MicroRNA and cancer</article-title>
<source>Mol. Oncol.</source>
<year>2012</year>
<volume>6</volume>
<fpage>590</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1016/j.molonc.2012.09.006</pub-id>
<?supplied-pmid 23102669?><pub-id pub-id-type="pmid">23102669</pub-id></element-citation></ref><ref id="B8-ijms-18-00507"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>L.K.</given-names></name><name><surname>Pope</surname><given-names>C.</given-names></name><name><surname>Botha</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Patients&#x02019; help-seeking experiences and delay in cancer presentation: A qualitative synthesis</article-title>
<source>Lancet</source>
<year>2005</year>
<volume>366</volume>
<fpage>3</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)67030-4</pub-id>
<pub-id pub-id-type="pmid">15993209</pub-id></element-citation></ref><ref id="B9-ijms-18-00507"><label>9.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Howlader</surname><given-names>N.</given-names></name><name><surname>Noone</surname><given-names>A.M.</given-names></name><name><surname>Krapcho</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>D.</given-names></name><name><surname>Bishop</surname><given-names>K.</given-names></name><name><surname>Altekruse</surname><given-names>S.F.</given-names></name><name><surname>Kosary</surname><given-names>C.L.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Ruhl</surname><given-names>J.</given-names></name><name><surname>Tatalovich</surname><given-names>Z.</given-names></name><etal/></person-group>
<source>SEER Cancer Statistics Review, 1975-2013</source>
<publisher-name>National Cancer Institute</publisher-name>
<publisher-loc>Bethesda, MD, USA</publisher-loc>
<year>2016</year>
</element-citation></ref><ref id="B10-ijms-18-00507"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>P.O.</given-names></name><name><surname>Palmer</surname><given-names>C.</given-names></name></person-group>
<article-title>The preclinical natural history of serous ovarian cancer: Defining the target for early detection</article-title>
<source>PLoS Med.</source>
<year>2009</year>
<volume>6</volume>
<elocation-id>e1000114</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1000114</pub-id>
<?supplied-pmid 19636370?><pub-id pub-id-type="pmid">19636370</pub-id></element-citation></ref><ref id="B11-ijms-18-00507"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schildkraut</surname><given-names>J.M.</given-names></name><name><surname>Bastos</surname><given-names>E.</given-names></name><name><surname>Berchuck</surname><given-names>A.</given-names></name></person-group>
<article-title>Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer</article-title>
<source>J. Natl. Cancer Inst.</source>
<year>1997</year>
<volume>89</volume>
<fpage>932</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/89.13.932</pub-id>
<?supplied-pmid 9214672?><pub-id pub-id-type="pmid">9214672</pub-id></element-citation></ref><ref id="B12-ijms-18-00507"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hunn</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>G.</given-names></name></person-group>
<article-title>Ovarian cancer: Etiology, risk factors, and epidemiology</article-title>
<source>Clin. Obstet. Gynecol.</source>
<year>2012</year>
<volume>55</volume>
<fpage>3</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1097/GRF.0b013e31824b4611</pub-id>
<?supplied-pmid 22343225?><pub-id pub-id-type="pmid">22343225</pub-id></element-citation></ref><ref id="B13-ijms-18-00507"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faber</surname><given-names>M.T.</given-names></name><name><surname>Kj&#x000e6;r</surname><given-names>S.K.</given-names></name><name><surname>Dehlendorff</surname><given-names>C.</given-names></name><name><surname>Chang-Claude</surname><given-names>J.</given-names></name><name><surname>Andersen</surname><given-names>K.K.</given-names></name><name><surname>H&#x000f8;gdall</surname><given-names>E.</given-names></name><name><surname>Webb</surname><given-names>P.</given-names></name><name><surname>Jordan</surname><given-names>S.</given-names></name><name><surname>Rossing</surname><given-names>M.A.</given-names></name><name><surname>Doherty</surname><given-names>J.A.</given-names></name><etal/></person-group>
<article-title>Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case-control studies</article-title>
<source>Cancer Cause Control</source>
<year>2013</year>
<volume>24</volume>
<fpage>989</fpage>
<lpage>1004</lpage>
<pub-id pub-id-type="doi">10.1007/s10552-013-0174-4</pub-id>
<?supplied-pmid 23456270?><pub-id pub-id-type="pmid">23456270</pub-id></element-citation></ref><ref id="B14-ijms-18-00507"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>C.M.</given-names></name><name><surname>Nagle</surname><given-names>C.M.</given-names></name><name><surname>Whiteman</surname><given-names>D.C.</given-names></name><name><surname>Ness</surname><given-names>R.</given-names></name><name><surname>Pearce</surname><given-names>C.L.</given-names></name><name><surname>Pike</surname><given-names>M.C.</given-names></name><name><surname>Rossing</surname><given-names>M.A.</given-names></name><name><surname>Terry</surname><given-names>K.L.</given-names></name><name><surname>Wu</surname><given-names>A.H.</given-names></name><collab>Australian Cancer Study (Ovarian Cancer)</collab><etal/></person-group>
<article-title>Obesity and risk of ovarian cancer subtypes: Evidence from the ovarian cancer association consortium</article-title>
<source>Endocr. Related Cancer</source>
<year>2013</year>
<volume>20</volume>
<fpage>251</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1530/ERC-12-0395</pub-id>
<?supplied-pmid 23404857?><pub-id pub-id-type="pmid">23404857</pub-id></element-citation></ref><ref id="B15-ijms-18-00507"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hein</surname><given-names>A.</given-names></name><name><surname>Thiel</surname><given-names>F.C.</given-names></name><name><surname>Bayer</surname><given-names>C.M.</given-names></name><name><surname>Fasching</surname><given-names>P.A.</given-names></name><name><surname>H&#x000e4;berle</surname><given-names>L.</given-names></name><name><surname>Lux</surname><given-names>M.P.</given-names></name><name><surname>Renner</surname><given-names>S.P.</given-names></name><name><surname>Jud</surname><given-names>S.M.</given-names></name><name><surname>Schrauder</surname><given-names>M.G.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Hormone replacement therapy and prognosis in ovarian cancer patients</article-title>
<source>Eur. J. Cancer Prev.</source>
<year>2013</year>
<volume>22</volume>
<fpage>52</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1097/CEJ.0b013e328355ec22</pub-id>
<?supplied-pmid 22694828?><pub-id pub-id-type="pmid">22694828</pub-id></element-citation></ref><ref id="B16-ijms-18-00507"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kurman</surname><given-names>R.J.</given-names></name><name><surname>Shih</surname><given-names>I.M.</given-names></name></person-group>
<article-title>The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded</article-title>
<source>Am. J. Pathol.</source>
<year>2016</year>
<volume>186</volume>
<fpage>733</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2015.11.011</pub-id>
<?supplied-pmid 27012190?><pub-id pub-id-type="pmid">27012190</pub-id></element-citation></ref><ref id="B17-ijms-18-00507"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeppernick</surname><given-names>F.</given-names></name><name><surname>Meinhold-Heerlein</surname><given-names>I.</given-names></name></person-group>
<article-title>The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer</article-title>
<source>Archiv. Gynecol. Obstet.</source>
<year>2014</year>
<volume>290</volume>
<fpage>839</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="doi">10.1007/s00404-014-3364-8</pub-id>
<?supplied-pmid 25082067?><pub-id pub-id-type="pmid">25082067</pub-id></element-citation></ref><ref id="B18-ijms-18-00507"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>L.</given-names></name><name><surname>Basso</surname><given-names>O.</given-names></name><name><surname>Sampalis</surname><given-names>J.</given-names></name><name><surname>Karp</surname><given-names>I.</given-names></name><name><surname>Martins</surname><given-names>C.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Piedimonte</surname><given-names>S.</given-names></name><name><surname>Quintal</surname><given-names>L.</given-names></name><name><surname>Ramanakumar</surname><given-names>A.V.</given-names></name><name><surname>Takefman</surname><given-names>J.</given-names></name></person-group>
<article-title>Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project</article-title>
<source>Lancet Oncol.</source>
<year>2012</year>
<volume>13</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(11)70333-3</pub-id>
<pub-id pub-id-type="pmid">22257524</pub-id></element-citation></ref><ref id="B19-ijms-18-00507"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>P.M.</given-names></name><name><surname>Bast</surname><given-names>R.B.</given-names></name></person-group>
<article-title>Early detection of ovarian cancer</article-title>
<source>Biomark. Med.</source>
<year>2008</year>
<volume>2</volume>
<fpage>291</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.2217/17520363.2.3.291</pub-id>
<?supplied-pmid 20477415?><pub-id pub-id-type="pmid">20477415</pub-id></element-citation></ref><ref id="B20-ijms-18-00507"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chi</surname><given-names>D.S.</given-names></name><name><surname>Eisenhauer</surname><given-names>E.L.</given-names></name><name><surname>Lang</surname><given-names>J.</given-names></name><name><surname>Huh</surname><given-names>J.</given-names></name><name><surname>Haddad</surname><given-names>L.</given-names></name><name><surname>Abu-Rustum</surname><given-names>N.R.</given-names></name><name><surname>Sonoda</surname><given-names>Y.</given-names></name><name><surname>Levine</surname><given-names>D.A.</given-names></name><name><surname>Hensley</surname><given-names>M.</given-names></name><name><surname>Barakat</surname><given-names>R.R.</given-names></name></person-group>
<article-title>What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?</article-title>
<source>Gynecol. Oncol.</source>
<year>2006</year>
<volume>103</volume>
<fpage>559</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2006.03.051</pub-id>
<?supplied-pmid 16714056?><pub-id pub-id-type="pmid">16714056</pub-id></element-citation></ref><ref id="B21-ijms-18-00507"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seidman</surname><given-names>J.D.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Yemelyanova</surname><given-names>A.</given-names></name></person-group>
<article-title>&#x0201c;Primary peritoneal&#x0201d; high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer</article-title>
<source>Gynecol. Oncol.</source>
<year>2011</year>
<volume>120</volume>
<fpage>470</fpage>
<lpage>473</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2010.11.020</pub-id>
<?supplied-pmid 21159368?><pub-id pub-id-type="pmid">21159368</pub-id></element-citation></ref><ref id="B22-ijms-18-00507"><label>22.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><collab>National Institute for Health and Care Excellence (NICE)</collab></person-group>
<article-title>Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/guidance/CG122">http://www.nice.org.uk/guidance/CG122</ext-link></comment>
<date-in-citation>(accessed on 20 December 2016)</date-in-citation>
</element-citation></ref><ref id="B23-ijms-18-00507"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van der Burg</surname><given-names>M.E.</given-names></name><name><surname>van Lent</surname><given-names>M.</given-names></name><name><surname>Buyse</surname><given-names>M.</given-names></name><name><surname>Kobierska</surname><given-names>A.</given-names></name><name><surname>Colombo</surname><given-names>N.</given-names></name><name><surname>Favalli</surname><given-names>G.</given-names></name><name><surname>Lacave</surname><given-names>A.J.</given-names></name><name><surname>Nardi</surname><given-names>M.</given-names></name><name><surname>Renard</surname><given-names>J.</given-names></name><name><surname>Pecorelli</surname><given-names>S.</given-names></name></person-group>
<article-title>The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer</article-title>
<source>N. Engl. J. Med.</source>
<year>1995</year>
<volume>332</volume>
<fpage>629</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199503093321002</pub-id>
<?supplied-pmid 7845426?><pub-id pub-id-type="pmid">7845426</pub-id></element-citation></ref><ref id="B24-ijms-18-00507"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Kaye</surname><given-names>S.B.</given-names></name></person-group>
<article-title>New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential</article-title>
<source>Clin. Cancer Res.</source>
<year>2012</year>
<volume>19</volume>
<fpage>961</fpage>
<lpage>968</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2243</pub-id>
<?supplied-pmid 23307860?><pub-id pub-id-type="pmid">23307860</pub-id></element-citation></ref><ref id="B25-ijms-18-00507"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katsumata</surname><given-names>N.</given-names></name><name><surname>Yasuda</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>F.</given-names></name><name><surname>Isonishi</surname><given-names>S.</given-names></name><name><surname>Jobo</surname><given-names>T.</given-names></name><name><surname>Aoki</surname><given-names>D.</given-names></name><name><surname>Tsuda</surname><given-names>H.</given-names></name><name><surname>Sugiyama</surname><given-names>T.</given-names></name><name><surname>Kodama</surname><given-names>S.</given-names></name><name><surname>Kimura</surname><given-names>E.</given-names></name><etal/></person-group>
<article-title>Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial</article-title>
<source>Lancet</source>
<year>2009</year>
<volume>374</volume>
<fpage>1331</fpage>
<lpage>1338</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(09)61157-0</pub-id>
<pub-id pub-id-type="pmid">19767092</pub-id></element-citation></ref><ref id="B26-ijms-18-00507"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jelovac</surname><given-names>D.</given-names></name><name><surname>Armstrong</surname><given-names>D.K.</given-names></name></person-group>
<article-title>Recent progress in the diagnosis and treatment of ovarian cancer</article-title>
<source>CA Cancer J. Clin.</source>
<year>2011</year>
<volume>61</volume>
<fpage>183</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.3322/caac.20113</pub-id>
<?supplied-pmid 21521830?><pub-id pub-id-type="pmid">21521830</pub-id></element-citation></ref><ref id="B27-ijms-18-00507"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayson</surname><given-names>G.C.</given-names></name><name><surname>Kohn</surname><given-names>E.C.</given-names></name><name><surname>Kitchener</surname><given-names>H.C.</given-names></name><name><surname>Ledermann</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Ovarian cancer</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>384</volume>
<fpage>1376</fpage>
<lpage>1388</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)62146-7</pub-id>
<pub-id pub-id-type="pmid">24767708</pub-id></element-citation></ref><ref id="B28-ijms-18-00507"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markman</surname><given-names>M.</given-names></name><name><surname>Markman</surname><given-names>J.</given-names></name><name><surname>Webster</surname><given-names>K.</given-names></name><name><surname>Zanotti</surname><given-names>K.</given-names></name><name><surname>Kulp</surname><given-names>B.</given-names></name><name><surname>Peterson</surname><given-names>G.</given-names></name><name><surname>Belinson</surname><given-names>J.</given-names></name></person-group>
<article-title>Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design</article-title>
<source>J. Clin. Oncol.</source>
<year>2004</year>
<volume>22</volume>
<fpage>3120</fpage>
<lpage>3125</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2004.05.195</pub-id>
<?supplied-pmid 15284263?><pub-id pub-id-type="pmid">15284263</pub-id></element-citation></ref><ref id="B29-ijms-18-00507"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torre</surname><given-names>L.A.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group>
<article-title>Global cancer statistics, 2012</article-title>
<source>CA Cancer J. Clin.</source>
<year>2015</year>
<volume>65</volume>
<fpage>87</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.3322/caac.21262</pub-id>
<?supplied-pmid 25651787?><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="B30-ijms-18-00507"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Low</surname><given-names>J.</given-names></name><name><surname>Ilancheran</surname><given-names>A.</given-names></name><name><surname>Ng</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Malignant ovarian germ-cell tumours</article-title>
<source>Best. Pract. Res. Clin. Obstet.</source>
<year>2012</year>
<volume>26</volume>
<fpage>347</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="doi">10.1016/j.bpobgyn.2012.01.002</pub-id>
<?supplied-pmid 22301054?><pub-id pub-id-type="pmid">22301054</pub-id></element-citation></ref><ref id="B31-ijms-18-00507"><label>31.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Garbi</surname><given-names>A.</given-names></name><name><surname>Achilarre</surname><given-names>M.T.</given-names></name><name><surname>Colombo</surname><given-names>N.</given-names></name></person-group>
<article-title>Ovarian Sex-Cord Tumors</article-title>
<source>Ovarian Cancers</source>
<person-group person-group-type="editor"><name><surname>Pujade-Lauraine</surname><given-names>E.</given-names></name><name><surname>Ray-Coquard</surname><given-names>I.</given-names></name><name><surname>L&#x000e9;curu</surname><given-names>F.</given-names></name></person-group>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham, Switzerland</publisher-loc>
<year>2016</year>
<fpage>261</fpage>
<lpage>279</lpage>
</element-citation></ref><ref id="B32-ijms-18-00507"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Auersperg</surname><given-names>N.</given-names></name><name><surname>Wong</surname><given-names>A.S.</given-names></name><name><surname>Choi</surname><given-names>K.C.</given-names></name><name><surname>Kang</surname><given-names>S.K.</given-names></name><name><surname>Leung</surname><given-names>P.C.</given-names></name></person-group>
<article-title>Ovarian surface epithelium: Biology, endocrinology, and pathology</article-title>
<source>Endocr. Rev.</source>
<year>2001</year>
<volume>22</volume>
<fpage>255</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1210/er.22.2.255</pub-id>
<?supplied-pmid 11294827?><pub-id pub-id-type="pmid">11294827</pub-id></element-citation></ref><ref id="B33-ijms-18-00507"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matz</surname><given-names>M.</given-names></name><name><surname>Coleman</surname><given-names>M.P.</given-names></name><name><surname>Carreira</surname><given-names>H.</given-names></name><name><surname>Salmer&#x000f3;n</surname><given-names>D.</given-names></name><name><surname>Chirlaque</surname><given-names>M.D.</given-names></name><name><surname>Allemani</surname><given-names>C.</given-names></name></person-group>
<article-title>The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)</article-title>
<source>Ginecol. Oncol.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2016.10.019</pub-id>
<?supplied-pmid 27931752?><pub-id pub-id-type="pmid">27931752</pub-id></element-citation></ref><ref id="B34-ijms-18-00507"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pharoah</surname><given-names>P.D.</given-names></name><name><surname>Ponder</surname><given-names>B.A.</given-names></name></person-group>
<article-title>The genetics of ovarian cancer</article-title>
<source>Best Pract. Res. Clin. Obstet. Gynaecol.</source>
<year>2002</year>
<volume>16</volume>
<fpage>449</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1053/beog.2002.0296</pub-id>
<?supplied-pmid 12413928?><pub-id pub-id-type="pmid">12413928</pub-id></element-citation></ref><ref id="B35-ijms-18-00507"><label>35.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Petrucelli</surname><given-names>N.</given-names></name><name><surname>Daly</surname><given-names>M.B.</given-names></name><name><surname>Pal</surname><given-names>T.</given-names></name></person-group>
<article-title>BRCA1 and BRCA2 Associated Hereditary Breast and Ovarian Cancer</article-title>
<source>GeneReviews&#x000ae;</source>
<person-group person-group-type="editor"><name><surname>Pagon</surname><given-names>R.A.</given-names></name><name><surname>Adam</surname><given-names>M.P.</given-names></name><name><surname>Ardinger</surname><given-names>H.H.</given-names></name><name><surname>Wallace</surname><given-names>S.E.</given-names></name><name><surname>Amemiya</surname><given-names>A.</given-names></name><name><surname>Bean</surname><given-names>L.J.H.</given-names></name><name><surname>Bird</surname><given-names>T.D.</given-names></name><name><surname>Ledbetter</surname><given-names>N.</given-names></name><name><surname>Mefford</surname><given-names>H.C.</given-names></name><name><surname>Smith</surname><given-names>R.J.H.</given-names></name></person-group>
<publisher-name>University of Washington</publisher-name>
<publisher-loc>Seattle, WA, USA</publisher-loc>
<year>1998</year>
</element-citation></ref><ref id="B36-ijms-18-00507"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowe</surname><given-names>K.A.</given-names></name><name><surname>Chia</surname><given-names>V.M.</given-names></name><name><surname>Taylor</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>C.</given-names></name><name><surname>Kelsh</surname><given-names>M.</given-names></name><name><surname>Mohamed</surname><given-names>M.</given-names></name><name><surname>Mowat</surname><given-names>F.S.</given-names></name><name><surname>Goff</surname><given-names>B.</given-names></name></person-group>
<article-title>An international assessment of ovarian cancer incidence and mortality</article-title>
<source>Gynecol. Oncol.</source>
<year>2013</year>
<volume>130</volume>
<fpage>107</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2013.03.026</pub-id>
<?supplied-pmid 23558050?><pub-id pub-id-type="pmid">23558050</pub-id></element-citation></ref><ref id="B37-ijms-18-00507"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dubeau</surname><given-names>L.</given-names></name><name><surname>Drapkin</surname><given-names>R.</given-names></name></person-group>
<article-title>Coming into focus: The nonovarian origins of ovarian cancer</article-title>
<source>Ann. Oncol.</source>
<year>2013</year>
<volume>24</volume>
<fpage>28</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdt308</pub-id>
<?supplied-pmid 24131966?><pub-id pub-id-type="pmid">24131966</pub-id></element-citation></ref><ref id="B38-ijms-18-00507"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erickson</surname><given-names>B.K.</given-names></name><name><surname>Conner</surname><given-names>M.G.</given-names></name><name><surname>Landen</surname><given-names>C.N.</given-names></name></person-group>
<article-title>The role of the fallopian tube in the origin of ovarian cancer</article-title>
<source>Am. J. Obstet. Gynecol.</source>
<year>2013</year>
<volume>209</volume>
<fpage>409</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajog.2013.04.019</pub-id>
<?supplied-pmid 23583217?><pub-id pub-id-type="pmid">23583217</pub-id></element-citation></ref><ref id="B39-ijms-18-00507"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group>
<article-title>Hallmarks of cancer: The next generation</article-title>
<source>Cell</source>
<year>2011</year>
<volume>144</volume>
<fpage>646</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
<?supplied-pmid 21376230?><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B40-ijms-18-00507"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P.</given-names></name><name><surname>Jain</surname><given-names>R.K.</given-names></name></person-group>
<article-title>Angiogenesis in cancer and other diseases</article-title>
<source>Nature</source>
<year>2000</year>
<volume>407</volume>
<fpage>249</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1038/35025220</pub-id>
<?supplied-pmid 11001068?><pub-id pub-id-type="pmid">11001068</pub-id></element-citation></ref><ref id="B41-ijms-18-00507"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P.</given-names></name></person-group>
<article-title>VEGF as a key mediator of angiogenesis in cancer</article-title>
<source>Oncology</source>
<year>2005</year>
<volume>69</volume>
<fpage>4</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1159/000088478</pub-id>
<?supplied-pmid 16301830?><pub-id pub-id-type="pmid">16301830</pub-id></element-citation></ref><ref id="B42-ijms-18-00507"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Frantz</surname><given-names>G.</given-names></name><name><surname>LeCouter</surname><given-names>J.</given-names></name><name><surname>Dillard-Telm</surname><given-names>L.</given-names></name><name><surname>Pham</surname><given-names>T.</given-names></name><name><surname>Draksharapu</surname><given-names>A.</given-names></name><name><surname>Giordano</surname><given-names>T.</given-names></name><name><surname>Peale</surname><given-names>F.</given-names></name></person-group>
<article-title>Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries</article-title>
<source>Am. J. Pathol.</source>
<year>2003</year>
<volume>162</volume>
<fpage>1881</fpage>
<lpage>1893</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)64322-2</pub-id>
<pub-id pub-id-type="pmid">12759245</pub-id></element-citation></ref><ref id="B43-ijms-18-00507"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Wellman</surname><given-names>T.L.</given-names></name><name><surname>Lounsbury</surname><given-names>K.M.</given-names></name></person-group>
<article-title>VEGF and HIF-1&#x003b1; expression are increased in advanced stages of epithelial ovarian cancer</article-title>
<source>Gynecol. Oncol.</source>
<year>2003</year>
<volume>91</volume>
<fpage>513</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2003.08.022</pub-id>
<?supplied-pmid 14675669?><pub-id pub-id-type="pmid">14675669</pub-id></element-citation></ref><ref id="B44-ijms-18-00507"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pujade-Lauraine</surname><given-names>E.</given-names></name><name><surname>Hilpert</surname><given-names>F.</given-names></name><name><surname>Weber</surname><given-names>B.</given-names></name><name><surname>Reuss</surname><given-names>A.</given-names></name><name><surname>Poveda</surname><given-names>A.</given-names></name><name><surname>Kristensen</surname><given-names>G.</given-names></name><name><surname>Sorio</surname><given-names>R.</given-names></name><name><surname>Vergote</surname><given-names>I.</given-names></name><name><surname>Witteveen</surname><given-names>P.</given-names></name><name><surname>Bamias</surname><given-names>A.</given-names></name></person-group>
<article-title>Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial</article-title>
<source>J. Clin. Oncol.</source>
<year>2014</year>
<volume>32</volume>
<fpage>1302</fpage>
<lpage>1308</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2013.51.4489</pub-id>
<?supplied-pmid 24637997?><pub-id pub-id-type="pmid">24637997</pub-id></element-citation></ref><ref id="B45-ijms-18-00507"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oza</surname><given-names>A.M.</given-names></name><name><surname>Cook</surname><given-names>A.D.</given-names></name><name><surname>Pfisterer</surname><given-names>J.</given-names></name><name><surname>Embleton</surname><given-names>A.</given-names></name><name><surname>Ledermann</surname><given-names>J.A.</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E.</given-names></name><name><surname>Kristensen</surname><given-names>G.</given-names></name><name><surname>Carey</surname><given-names>M.S.</given-names></name><name><surname>Beale</surname><given-names>P.</given-names></name><name><surname>Cervantes</surname><given-names>A.</given-names></name></person-group>
<article-title>Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial</article-title>
<source>Lancet Oncol.</source>
<year>2015</year>
<volume>16</volume>
<fpage>928</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(15)00086-8</pub-id>
<pub-id pub-id-type="pmid">26115797</pub-id></element-citation></ref><ref id="B46-ijms-18-00507"><label>46.</label><element-citation publication-type="webpage">
<article-title>The Electronic Medicines Compendium. Avastin 25 mg/mL Concentrate for Solution for Infusion</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/medicine/15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/">https://www.medicines.org.uk/emc/medicine/15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/</ext-link></comment>
<date-in-citation>(accessed on 16 December 2016)</date-in-citation>
</element-citation></ref><ref id="B47-ijms-18-00507"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gschwind</surname><given-names>A.</given-names></name><name><surname>Fischer</surname><given-names>O.M.</given-names></name><name><surname>Ullrich</surname><given-names>A.</given-names></name></person-group>
<article-title>The discovery of receptor tyrosine kinases: Targets for cancer therapy</article-title>
<source>Nat. Rev. Cancer</source>
<year>2004</year>
<volume>4</volume>
<fpage>361</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="doi">10.1038/nrc1360</pub-id>
<?supplied-pmid 15122207?><pub-id pub-id-type="pmid">15122207</pub-id></element-citation></ref><ref id="B48-ijms-18-00507"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakagawara</surname><given-names>A.</given-names></name></person-group>
<article-title>TRK receptor tyrosine kinases: A bridge between cancer and neural development</article-title>
<source>Cancer Lett.</source>
<year>2001</year>
<volume>169</volume>
<fpage>107</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3835(01)00530-4</pub-id>
<pub-id pub-id-type="pmid">11431098</pub-id></element-citation></ref><ref id="B49-ijms-18-00507"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewin</surname><given-names>G.R.</given-names></name><name><surname>Barde</surname><given-names>Y.A.</given-names></name></person-group>
<article-title>Physiology of the neurotrophins</article-title>
<source>Annu. Rev. Neurosci.</source>
<year>1996</year>
<volume>19</volume>
<fpage>289</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.ne.19.030196.001445</pub-id>
<?supplied-pmid 8833445?><pub-id pub-id-type="pmid">8833445</pub-id></element-citation></ref><ref id="B50-ijms-18-00507"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chao</surname><given-names>M.V.</given-names></name><name><surname>Hempstead</surname><given-names>B.L.</given-names></name></person-group>
<article-title>p75 and TRK: A two-receptor system</article-title>
<source>Trends Neurosci.</source>
<year>1995</year>
<volume>18</volume>
<fpage>321</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1016/0166-2236(95)93922-K</pub-id>
<pub-id pub-id-type="pmid">7571013</pub-id></element-citation></ref><ref id="B51-ijms-18-00507"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chao</surname><given-names>M.V.</given-names></name></person-group>
<article-title>The p75 neurotrophin receptor</article-title>
<source>J. Neurobiol.</source>
<year>1994</year>
<volume>25</volume>
<fpage>1373</fpage>
<lpage>1385</lpage>
<pub-id pub-id-type="doi">10.1002/neu.480251106</pub-id>
<?supplied-pmid 7852992?><pub-id pub-id-type="pmid">7852992</pub-id></element-citation></ref><ref id="B52-ijms-18-00507"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patapoutian</surname><given-names>A.</given-names></name><name><surname>Reichardt</surname><given-names>L.F.</given-names></name></person-group>
<article-title>TRK receptors: Mediators of neurotrophin action</article-title>
<source>Curr. Opin. Neurobiol.</source>
<year>2001</year>
<volume>11</volume>
<fpage>272</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-4388(00)00208-7</pub-id>
<pub-id pub-id-type="pmid">11399424</pub-id></element-citation></ref><ref id="B53-ijms-18-00507"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aloe</surname><given-names>L.</given-names></name></person-group>
<article-title>Rita Levi-Montalcini and the discovery of NGF, the first nerve cell growth factor</article-title>
<source>Arch. Ital. Biol.</source>
<year>2011</year>
<volume>149</volume>
<fpage>175</fpage>
<lpage>181</lpage>
<?supplied-pmid 21701989?><pub-id pub-id-type="pmid">21701989</pub-id></element-citation></ref><ref id="B54-ijms-18-00507"><label>54.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Hein</surname><given-names>L.</given-names></name></person-group>
<article-title>The Neuroendocrine Adrenergic System and Cardiovascular Function</article-title>
<source>The Cardiovascular Adrenergic System</source>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham, Switzerland</publisher-loc>
<year>2015</year>
<fpage>117</fpage>
<lpage>132</lpage>
</element-citation></ref><ref id="B55-ijms-18-00507"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Procaccini</surname><given-names>C.</given-names></name><name><surname>Pucino</surname><given-names>V.</given-names></name><name><surname>de Rosa</surname><given-names>V.</given-names></name><name><surname>Marone</surname><given-names>G.</given-names></name><name><surname>Matarese</surname><given-names>G.</given-names></name></person-group>
<article-title>Neuro-endocrine networks controlling immune system in health and disease</article-title>
<source>Front. Immunol.</source>
<year>2014</year>
<volume>5</volume>
<fpage>143</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00143</pub-id>
<?supplied-pmid 24778633?><pub-id pub-id-type="pmid">24778633</pub-id></element-citation></ref><ref id="B56-ijms-18-00507"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Streiter</surname><given-names>S.</given-names></name><name><surname>Fisch</surname><given-names>B.</given-names></name><name><surname>Sabbah</surname><given-names>B.</given-names></name><name><surname>Ao</surname><given-names>A.</given-names></name><name><surname>Abir</surname><given-names>R.</given-names></name></person-group>
<article-title>The importance of neuronal growth factors in the ovary</article-title>
<source>Mol. Hum Reprod.</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.1093/molehr/gav057</pub-id>
<?supplied-pmid 26487421?><pub-id pub-id-type="pmid">26487421</pub-id></element-citation></ref><ref id="B57-ijms-18-00507"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaves</surname><given-names>R.N.</given-names></name><name><surname>Alves</surname><given-names>A.M.</given-names></name><name><surname>Lima</surname><given-names>L.F.</given-names></name><name><surname>Matos</surname><given-names>H.M.</given-names></name><name><surname>Rodrigues</surname><given-names>A.P.</given-names></name><name><surname>Figueiredo</surname><given-names>J.R.</given-names></name></person-group>
<article-title>Role of nerve growth factor (NGF) and its receptors in folliculogenesis</article-title>
<source>Zygote</source>
<year>2013</year>
<volume>21</volume>
<fpage>187</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1017/S0967199412000111</pub-id>
<?supplied-pmid 22651979?><pub-id pub-id-type="pmid">22651979</pub-id></element-citation></ref><ref id="B58-ijms-18-00507"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dissen</surname><given-names>G.A.</given-names></name><name><surname>Parrott</surname><given-names>J.A.</given-names></name><name><surname>Skinner</surname><given-names>M.K.</given-names></name><name><surname>Hill</surname><given-names>D.F.</given-names></name><name><surname>Costa</surname><given-names>M.E.</given-names></name><name><surname>Ojeda</surname><given-names>S.R.</given-names></name></person-group>
<article-title>Direct effects of nerve growth factor on thecal cells from antral ovarian follicles</article-title>
<source>Endocrinology</source>
<year>2000</year>
<volume>141</volume>
<fpage>4736</fpage>
<lpage>4750</lpage>
<pub-id pub-id-type="doi">10.1210/en.141.12.4736</pub-id>
<?supplied-pmid 11108289?><pub-id pub-id-type="pmid">11108289</pub-id></element-citation></ref><ref id="B59-ijms-18-00507"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>N.</given-names></name><name><surname>Liang</surname><given-names>M.</given-names></name><name><surname>Yao</surname><given-names>G.</given-names></name><name><surname>Cui</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name></person-group>
<article-title>NGF promotes mouse granulosa cell proliferation by inhibiting ESR2 mediated down-regulation of CDKN1A</article-title>
<source>Mol. Cell. Endocrinol.</source>
<year>2015</year>
<volume>406</volume>
<fpage>68</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.mce.2015.02.024</pub-id>
<?supplied-pmid 25737208?><pub-id pub-id-type="pmid">25737208</pub-id></element-citation></ref><ref id="B60-ijms-18-00507"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dissen</surname><given-names>G.A.</given-names></name><name><surname>Hill</surname><given-names>D.F.</given-names></name><name><surname>Costa</surname><given-names>M.E.</given-names></name><name><surname>Les Dees</surname><given-names>C.W.</given-names></name><name><surname>Lara</surname><given-names>H.E.</given-names></name><name><surname>Ojeda</surname><given-names>S.R.</given-names></name></person-group>
<article-title>A role for TRKA nerve growth factor receptors in mammalian ovulation</article-title>
<source>Endocrinology</source>
<year>1996</year>
<volume>137</volume>
<fpage>198</fpage>
<lpage>209</lpage>
<?supplied-pmid 8536613?><pub-id pub-id-type="pmid">8536613</pub-id></element-citation></ref><ref id="B61-ijms-18-00507"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romero</surname><given-names>C.</given-names></name><name><surname>Paredes</surname><given-names>A.</given-names></name><name><surname>Dissen</surname><given-names>G.A.</given-names></name><name><surname>Ojeda</surname><given-names>S.R.</given-names></name></person-group>
<article-title>Nerve growth factor induces the expression of functional FSH receptors in newly formed follicles of the rat ovary</article-title>
<source>Endocrinology</source>
<year>2002</year>
<volume>143</volume>
<fpage>1485</fpage>
<lpage>1494</lpage>
<pub-id pub-id-type="doi">10.1210/endo.143.4.8711</pub-id>
<?supplied-pmid 11897707?><pub-id pub-id-type="pmid">11897707</pub-id></element-citation></ref><ref id="B62-ijms-18-00507"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goede</surname><given-names>V.</given-names></name><name><surname>Schmidt</surname><given-names>T.</given-names></name><name><surname>Kimmina</surname><given-names>S.</given-names></name><name><surname>Kozian</surname><given-names>D.</given-names></name><name><surname>Augustin</surname><given-names>H.G.</given-names></name></person-group>
<article-title>Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis</article-title>
<source>Lab. Investig.</source>
<year>1998</year>
<volume>78</volume>
<fpage>1385</fpage>
<lpage>1394</lpage>
<?supplied-pmid 9840613?><pub-id pub-id-type="pmid">9840613</pub-id></element-citation></ref><ref id="B63-ijms-18-00507"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>RC.</given-names></name><name><surname>Xiao</surname><given-names>E.</given-names></name><name><surname>Husami</surname><given-names>N.</given-names></name><name><surname>Sauer</surname><given-names>M.V.</given-names></name><name><surname>Lobo</surname><given-names>R.</given-names></name><name><surname>Kitajewski</surname><given-names>J.</given-names></name><name><surname>Ferin</surname><given-names>M.</given-names></name></person-group>
<article-title>Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey</article-title>
<source>J. Clin. Endocrinol. Metab.</source>
<year>2001</year>
<volume>86</volume>
<fpage>768</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.1210/jc.86.2.768</pub-id>
<?supplied-pmid 11158044?><pub-id pub-id-type="pmid">11158044</pub-id></element-citation></ref><ref id="B64-ijms-18-00507"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Davis-Smyth</surname><given-names>T.</given-names></name><name><surname>Gerber</surname><given-names>H.-P.</given-names></name><name><surname>Nguyen</surname><given-names>T.-N.</given-names></name><name><surname>Peers</surname><given-names>D.</given-names></name><name><surname>Chisholm</surname><given-names>V.</given-names></name><name><surname>Hillan</surname><given-names>K.J.</given-names></name><name><surname>Schwall</surname><given-names>R.H.</given-names></name></person-group>
<article-title>Vascular endothelial growth factor is essential for corpus luteum angiogenesis</article-title>
<source>Nat. Med.</source>
<year>1998</year>
<volume>4</volume>
<fpage>336</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1038/nm0398-336</pub-id>
<?supplied-pmid 9500609?><pub-id pub-id-type="pmid">9500609</pub-id></element-citation></ref><ref id="B65-ijms-18-00507"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Konishi</surname><given-names>I.</given-names></name><name><surname>Tsuruta</surname><given-names>Y.</given-names></name><name><surname>Nanbu</surname><given-names>K.</given-names></name><name><surname>Mandai</surname><given-names>M.</given-names></name><name><surname>Kuroda</surname><given-names>H.</given-names></name><name><surname>Matsushita</surname><given-names>K.</given-names></name><name><surname>Hamid</surname><given-names>A.A.</given-names></name><name><surname>Yura</surname><given-names>Y.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name></person-group>
<article-title>Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary</article-title>
<source>Gynecol. Endocrinol.</source>
<year>1997</year>
<volume>11</volume>
<fpage>371</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="doi">10.3109/09513599709152564</pub-id>
<?supplied-pmid 9476086?><pub-id pub-id-type="pmid">9476086</pub-id></element-citation></ref><ref id="B66-ijms-18-00507"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hillier</surname><given-names>S.G.</given-names></name></person-group>
<article-title>Gonadotropic control of ovarian follicular growth and development</article-title>
<source>Mol. Cel. Endocrinol.</source>
<year>2001</year>
<volume>179</volume>
<fpage>39</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/S0303-7207(01)00469-5</pub-id>
</element-citation></ref><ref id="B67-ijms-18-00507"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cantarella</surname><given-names>G.</given-names></name><name><surname>Lempereur</surname><given-names>L.</given-names></name><name><surname>Presta</surname><given-names>M.</given-names></name><name><surname>Ribatti</surname><given-names>D.</given-names></name><name><surname>Lombardo</surname><given-names>G.</given-names></name><name><surname>Lazarovici</surname><given-names>P.</given-names></name><name><surname>Zappala</surname><given-names>G.</given-names></name><name><surname>Pafumi</surname><given-names>C.</given-names></name><name><surname>Bernardini</surname><given-names>R.</given-names></name></person-group>
<article-title>Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo</article-title>
<source>FASEB J.</source>
<year>2002</year>
<volume>16</volume>
<fpage>1307</fpage>
<lpage>1309</lpage>
<pub-id pub-id-type="doi">10.1096/fj.01-1000fje</pub-id>
<?supplied-pmid 12154004?><pub-id pub-id-type="pmid">12154004</pub-id></element-citation></ref><ref id="B68-ijms-18-00507"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calza</surname><given-names>L.</given-names></name><name><surname>Giardino</surname><given-names>L.</given-names></name><name><surname>Giuliani</surname><given-names>A.</given-names></name><name><surname>Aloe</surname><given-names>L.</given-names></name><name><surname>Levi-Montalcini</surname><given-names>R.</given-names></name></person-group>
<article-title>Nerve growth factor control of neuronal expression of angiogenic and vasoactive factors</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2001</year>
<volume>98</volume>
<fpage>4160</fpage>
<lpage>4165</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.051626998</pub-id>
<?supplied-pmid 11259645?><pub-id pub-id-type="pmid">11259645</pub-id></element-citation></ref><ref id="B69-ijms-18-00507"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salas</surname><given-names>C.</given-names></name><name><surname>Julio-Pieper</surname><given-names>M.</given-names></name><name><surname>Valladares</surname><given-names>M.</given-names></name><name><surname>Pommer</surname><given-names>R.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name><name><surname>Mastronardi</surname><given-names>C.</given-names></name><name><surname>Kerr</surname><given-names>B.</given-names></name><name><surname>Ojeda</surname><given-names>S.R.</given-names></name><name><surname>Lara</surname><given-names>H.E.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>Nerve growth factor-dependent activation of TRKA receptors in the human ovary results in synthesis of follicle-stimulating hormone receptors and estrogen secretion</article-title>
<source>J. Clin. Endocrinol. Metab.</source>
<year>2006</year>
<volume>91</volume>
<fpage>2396</fpage>
<lpage>2403</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2005-1925</pub-id>
<?supplied-pmid 16537688?><pub-id pub-id-type="pmid">16537688</pub-id></element-citation></ref><ref id="B70-ijms-18-00507"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bast</surname><given-names>R.C.</given-names></name><name><surname>Hennessy</surname><given-names>B.</given-names></name><name><surname>Mills</surname><given-names>G.B.</given-names></name></person-group>
<article-title>The biology of ovarian cancer: New opportunities for translation</article-title>
<source>Nat. Rev. Cancer</source>
<year>2009</year>
<volume>9</volume>
<fpage>415</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2644</pub-id>
<?supplied-pmid 19461667?><pub-id pub-id-type="pmid">19461667</pub-id></element-citation></ref><ref id="B71-ijms-18-00507"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Campos</surname><given-names>X.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>Y.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Yazigi</surname><given-names>R.</given-names></name><name><surname>Moyano</surname><given-names>L.</given-names></name><name><surname>Weinstein-Oppenheimer</surname><given-names>C.</given-names></name><name><surname>Lara</surname><given-names>H.E.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>Nerve growth factor and its high-affinity receptor TRKA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer</article-title>
<source>Gynecol. Oncol.</source>
<year>2007</year>
<volume>104</volume>
<fpage>168</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2006.07.007</pub-id>
<?supplied-pmid 16935322?><pub-id pub-id-type="pmid">16935322</pub-id></element-citation></ref><ref id="B72-ijms-18-00507"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Yao</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><etal/></person-group>
<article-title>Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer</article-title>
<source>Anticancer Res.</source>
<year>2004</year>
<volume>24</volume>
<fpage>1973</fpage>
<lpage>1979</lpage>
<?supplied-pmid 15274387?><pub-id pub-id-type="pmid">15274387</pub-id></element-citation></ref><ref id="B73-ijms-18-00507"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Gerber</surname><given-names>H.P.</given-names></name><name><surname>LeCouter</surname><given-names>J.</given-names></name></person-group>
<article-title>The biology of VEGF and its receptors</article-title>
<source>Nat. Med.</source>
<year>2003</year>
<volume>9</volume>
<fpage>669</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.1038/nm0603-669</pub-id>
<?supplied-pmid 12778165?><pub-id pub-id-type="pmid">12778165</pub-id></element-citation></ref><ref id="B74-ijms-18-00507"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adriaenssens</surname><given-names>E.</given-names></name><name><surname>Vanhecke</surname><given-names>E.</given-names></name><name><surname>Saule</surname><given-names>P.</given-names></name><name><surname>Mougel</surname><given-names>A.</given-names></name><name><surname>Page</surname><given-names>A.</given-names></name><name><surname>Romon</surname><given-names>R.</given-names></name><name><surname>Nurcombe</surname><given-names>V.</given-names></name><name><surname>Le Bourhis</surname><given-names>X.</given-names></name><name><surname>Hondermarck</surname><given-names>H.</given-names></name></person-group>
<article-title>Nerve growth factor is a potential therapeutic target in breast cancer</article-title>
<source>Cancer Res.</source>
<year>2008</year>
<volume>68</volume>
<fpage>346</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1183</pub-id>
<?supplied-pmid 18199526?><pub-id pub-id-type="pmid">18199526</pub-id></element-citation></ref><ref id="B75-ijms-18-00507"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walch</surname><given-names>E.T.</given-names></name><name><surname>Marchetti</surname><given-names>D.</given-names></name></person-group>
<article-title>Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostate cancer cells</article-title>
<source>Clin. Exp. Metastasis</source>
<year>1999</year>
<volume>17</volume>
<fpage>307</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1023/A:1006652605568</pub-id>
<?supplied-pmid 10545017?><pub-id pub-id-type="pmid">10545017</pub-id></element-citation></ref><ref id="B76-ijms-18-00507"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doll&#x000e9;</surname><given-names>L.</given-names></name><name><surname>Adriaenssens</surname><given-names>E.</given-names></name><name><surname>Yazidi-Belkoura</surname><given-names>I.E.</given-names></name><name><surname>Bourhis</surname><given-names>X.L.</given-names></name><name><surname>Nurcombe</surname><given-names>V.</given-names></name><name><surname>Hondermarck</surname><given-names>H.</given-names></name></person-group>
<article-title>Nerve growth factor receptors and signaling in breast cancer</article-title>
<source>Curr. Cancer Drug Targets</source>
<year>2004</year>
<volume>4</volume>
<fpage>463</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="doi">10.2174/1568009043332853</pub-id>
<?supplied-pmid 15379632?><pub-id pub-id-type="pmid">15379632</pub-id></element-citation></ref><ref id="B77-ijms-18-00507"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGregor</surname><given-names>L.M.</given-names></name><name><surname>McCune</surname><given-names>B.K.</given-names></name><name><surname>Graff</surname><given-names>J.R.</given-names></name><name><surname>McDowell</surname><given-names>P.R.</given-names></name><name><surname>Romans</surname><given-names>K.E.</given-names></name><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><name><surname>Ball</surname><given-names>D.W.</given-names></name><name><surname>Baylin</surname><given-names>S.B.</given-names></name><name><surname>Nelkin</surname><given-names>B.D.</given-names></name></person-group>
<article-title>Roles of TRK family neurotrophin receptors in medullary thyroid carcinoma development and progression</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1999</year>
<volume>96</volume>
<fpage>4540</fpage>
<lpage>4545</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.8.4540</pub-id>
<?supplied-pmid 10200298?><pub-id pub-id-type="pmid">10200298</pub-id></element-citation></ref><ref id="B78-ijms-18-00507"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ricci</surname><given-names>A.</given-names></name><name><surname>Greco</surname><given-names>S.</given-names></name><name><surname>Mariotta</surname><given-names>S.</given-names></name><name><surname>Felici</surname><given-names>L.</given-names></name><name><surname>Bronzetti</surname><given-names>E.</given-names></name><name><surname>Cavazzana</surname><given-names>A.</given-names></name><name><surname>Barbolini</surname><given-names>G.</given-names></name></person-group>
<article-title>Neurotrophins and neurotrophin receptors in human lung cancer</article-title>
<source>Am. J. Respir. Cell Mol. Biol.</source>
<year>2001</year>
<volume>25</volume>
<fpage>439</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="doi">10.1165/ajrcmb.25.4.4470</pub-id>
<?supplied-pmid 11694449?><pub-id pub-id-type="pmid">11694449</pub-id></element-citation></ref><ref id="B79-ijms-18-00507"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsunoda</surname><given-names>S.</given-names></name><name><surname>Okumura</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>Y.</given-names></name><name><surname>Soma</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>G.</given-names></name><name><surname>Kaganoi</surname><given-names>J.</given-names></name><name><surname>Itami</surname><given-names>A.</given-names></name><name><surname>Sakai</surname><given-names>Y.</given-names></name><name><surname>Shimada</surname><given-names>Y.</given-names></name></person-group>
<article-title>Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma</article-title>
<source>Br. J. Cancer</source>
<year>2006</year>
<volume>95</volume>
<fpage>322</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6603255</pub-id>
<?supplied-pmid 16832412?><pub-id pub-id-type="pmid">16832412</pub-id></element-citation></ref><ref id="B80-ijms-18-00507"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tapia</surname><given-names>V.</given-names></name><name><surname>Gabler</surname><given-names>F.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>M.</given-names></name><name><surname>Yazigi</surname><given-names>R.</given-names></name><name><surname>Paredes</surname><given-names>A.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>Tyrosine kinase A receptor (TRKA): A potential marker in epithelial ovarian cancer</article-title>
<source>Gynecol. Oncol.</source>
<year>2011</year>
<volume>121</volume>
<fpage>13</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2010.12.341</pub-id>
<?supplied-pmid 21236475?><pub-id pub-id-type="pmid">21236475</pub-id></element-citation></ref><ref id="B81-ijms-18-00507"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Urz&#x000fa;a</surname><given-names>U.</given-names></name><name><surname>Tapia</surname><given-names>V.</given-names></name><name><surname>Geraldo</surname><given-names>M.P.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>Nerve growth factor stimulates cellular proliferation of human epithelial ovarian cancer</article-title>
<source>Horm. Metab. Res.</source>
<year>2012</year>
<volume>44</volume>
<fpage>656</fpage>
<lpage>661</lpage>
<pub-id pub-id-type="doi">10.1055/s-0032-1304617</pub-id>
<?supplied-pmid 22411587?><pub-id pub-id-type="pmid">22411587</pub-id></element-citation></ref><ref id="B82-ijms-18-00507"><label>82.</label><element-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Romero</surname><given-names>C.</given-names></name><name><surname>Hurtado</surname><given-names>I.</given-names></name><name><surname>Garrido</surname><given-names>M.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name></person-group>
<article-title>The expression of coclooxigenase-2 is increased by nerve growth factor in epithelial ovarian cancer</article-title>
<source>Proceedings of the 24th Biennial Congress of the European Associtaion for Cancer Research</source>
<conf-loc>Manchester, UK</conf-loc>
<conf-date>9&#x02013;12 July 2016</conf-date>
</element-citation></ref><ref id="B83-ijms-18-00507"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tordjman</surname><given-names>C.</given-names></name><name><surname>Coge</surname><given-names>F.</given-names></name><name><surname>Andre</surname><given-names>N.</given-names></name><name><surname>Rique</surname><given-names>H.</given-names></name><name><surname>Spedding</surname><given-names>M.</given-names></name><name><surname>Bonnet</surname><given-names>J.</given-names></name></person-group>
<article-title>Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2</article-title>
<source>Biochim. Biophys. Acta</source>
<year>1995</year>
<volume>1256</volume>
<fpage>249</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1016/0005-2760(95)00026-9</pub-id>
<pub-id pub-id-type="pmid">7766705</pub-id></element-citation></ref><ref id="B84-ijms-18-00507"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Zhong</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name></person-group>
<article-title>The role of ADAM17 in tumorigenesis and progression of breast cancer</article-title>
<source>Tumour Biol.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1007/s13277-016-5418-y</pub-id>
<?supplied-pmid 27658778?><pub-id pub-id-type="pmid">27658778</pub-id></element-citation></ref><ref id="B85-ijms-18-00507"><label>85.</label><element-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Girardi</surname><given-names>S.</given-names></name><name><surname>Tapia</surname><given-names>V.</given-names></name><name><surname>Kohan</surname><given-names>K.</given-names></name><name><surname>Contreras</surname><given-names>H.</given-names></name><name><surname>Gabler</surname><given-names>F.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>ADAM17 and TRKA receptor are involved in epithelial ovarian cancer progression</article-title>
<source>Proceedings of the 17th World Congress on Advances in Oncology and 15th International Symposium on Molecular Medicine</source>
<conf-loc>Hersonissos, Greece</conf-loc>
<conf-date>11&#x02013;13 October 2012</conf-date>
</element-citation></ref><ref id="B86-ijms-18-00507"><label>86.</label><element-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Romero</surname><given-names>C.</given-names></name><name><surname>Vallejos</surname><given-names>C.</given-names></name><name><surname>Gabler</surname><given-names>F.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name></person-group>
<article-title>Activation of TRKA receptor by nerve growth factor induces shedding of p75 receptor related with progression of epithelial ovarian cancer</article-title>
<source>Proceedings of the 23rd Biennial Congress of the European Association for Cancer Research</source>
<conf-loc>Munich, Germany</conf-loc>
<conf-date>5&#x02013;8 July 2014</conf-date>
<fpage>5119</fpage>
<lpage>5120</lpage>
</element-citation></ref><ref id="B87-ijms-18-00507"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vera</surname><given-names>C.</given-names></name><name><surname>Tapia</surname><given-names>V.</given-names></name><name><surname>Kohan</surname><given-names>K.</given-names></name><name><surname>Gabler</surname><given-names>F.</given-names></name><name><surname>Ferreira</surname><given-names>A.</given-names></name><name><surname>Selman</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>C.</given-names></name></person-group>
<article-title>Nerve growth factor induces the expression of chaperone protein calreticulin in human epithelial ovarian cells</article-title>
<source>Horm. Metab. Res.</source>
<year>2012</year>
<volume>44</volume>
<fpage>639</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="doi">10.1055/s-0032-1311633</pub-id>
<?supplied-pmid 22773372?><pub-id pub-id-type="pmid">22773372</pub-id></element-citation></ref><ref id="B88-ijms-18-00507"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zamanian</surname><given-names>M.</given-names></name><name><surname>Qader Hamadneh</surname><given-names>L.A.</given-names></name><name><surname>Veerakumarasivam</surname><given-names>A.</given-names></name><name><surname>Abdul Rahman</surname><given-names>S.</given-names></name><name><surname>Shohaimi</surname><given-names>S.</given-names></name><name><surname>Rosli</surname><given-names>R.</given-names></name></person-group>
<article-title>Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways</article-title>
<source>Cancer Cell. Int.</source>
<year>2016</year>
<volume>16</volume>
<fpage>56</fpage>
<pub-id pub-id-type="doi">10.1186/s12935-016-0329-y</pub-id>
<?supplied-pmid 27418879?><pub-id pub-id-type="pmid">27418879</pub-id></element-citation></ref><ref id="B89-ijms-18-00507"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheng</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group>
<article-title>Overexpression of calreticulin contributes to the development and progression of pancreatic cancer</article-title>
<source>J. Cell. Physiol.</source>
<year>2014</year>
<volume>229</volume>
<fpage>887</fpage>
<lpage>897</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.24519</pub-id>
<?supplied-pmid 24264800?><pub-id pub-id-type="pmid">24264800</pub-id></element-citation></ref><ref id="B90-ijms-18-00507"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iwakawa</surname><given-names>H.O.</given-names></name><name><surname>Tomari</surname><given-names>Y.</given-names></name></person-group>
<article-title>The functions of microRNAs: mRNA decay and translational repression</article-title>
<source>Trends Cell Biol.</source>
<year>2015</year>
<volume>25</volume>
<fpage>651</fpage>
<lpage>665</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2015.07.011</pub-id>
<?supplied-pmid 26437588?><pub-id pub-id-type="pmid">26437588</pub-id></element-citation></ref><ref id="B91-ijms-18-00507"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zlotorynski</surname><given-names>E.</given-names></name></person-group>
<article-title>Small RNAs: New microRNA-like molecules</article-title>
<source>Nat. Rev. Mol. Cell Biol.</source>
<year>2016</year>
<volume>17</volume>
<fpage>396</fpage>
<pub-id pub-id-type="doi">10.1038/nrm.2016.84</pub-id>
<?supplied-pmid 27329963?><pub-id pub-id-type="pmid">27329963</pub-id></element-citation></ref><ref id="B92-ijms-18-00507"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winter</surname><given-names>J.</given-names></name><name><surname>Jung</surname><given-names>S.</given-names></name><name><surname>Keller</surname><given-names>S.</given-names></name><name><surname>Gregory</surname><given-names>R.I.</given-names></name><name><surname>Diederichs</surname><given-names>S.</given-names></name></person-group>
<article-title>Many roads to maturity: microRNA biogenesis pathways and their regulation</article-title>
<source>Nat. Cell Biol.</source>
<year>2009</year>
<volume>11</volume>
<fpage>228</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1038/ncb0309-228</pub-id>
<?supplied-pmid 19255566?><pub-id pub-id-type="pmid">19255566</pub-id></element-citation></ref><ref id="B93-ijms-18-00507"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ha</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>V.N.</given-names></name></person-group>
<article-title>Regulation of microRNA biogenesis</article-title>
<source>Nat. Rev. Mol. Cell Biol.</source>
<year>2014</year>
<volume>15</volume>
<fpage>509</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3838</pub-id>
<?supplied-pmid 25027649?><pub-id pub-id-type="pmid">25027649</pub-id></element-citation></ref><ref id="B94-ijms-18-00507"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molasy</surname><given-names>M.</given-names></name><name><surname>Walczak</surname><given-names>A.</given-names></name><name><surname>Szaflik</surname><given-names>J.</given-names></name><name><surname>Szaflik</surname><given-names>J.P.</given-names></name><name><surname>Majsterek</surname><given-names>I.</given-names></name></person-group>
<article-title>MicroRNAs in glaucoma and neurodegenerative diseases</article-title>
<source>J. Hum. Genet.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/jhg.2016.91</pub-id>
<?supplied-pmid 27412874?><pub-id pub-id-type="pmid">27412874</pub-id></element-citation></ref><ref id="B95-ijms-18-00507"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barwari</surname><given-names>T.</given-names></name><name><surname>Joshi</surname><given-names>A.</given-names></name><name><surname>Mayr</surname><given-names>M.</given-names></name></person-group>
<article-title>MicroRNAs in cardiovascular disease</article-title>
<source>J. Am. Coll. Cardiol.</source>
<year>2016</year>
<volume>68</volume>
<fpage>2577</fpage>
<lpage>2584</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2016.09.945</pub-id>
<?supplied-pmid 27931616?><pub-id pub-id-type="pmid">27931616</pub-id></element-citation></ref><ref id="B96-ijms-18-00507"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vienberg</surname><given-names>S.</given-names></name><name><surname>Geiger</surname><given-names>J.</given-names></name><name><surname>Madsen</surname><given-names>S.</given-names></name><name><surname>Dalgaard</surname><given-names>L.T.</given-names></name></person-group>
<article-title>MicroRNAs in metabolism</article-title>
<source>Acta Physiol.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1111/apha.12681</pub-id>
<?supplied-pmid 27009502?><pub-id pub-id-type="pmid">27009502</pub-id></element-citation></ref><ref id="B97-ijms-18-00507"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>K.B.</given-names></name></person-group>
<article-title>MicroRNA (miRNA) in cancer</article-title>
<source>Cancer Cell Int.</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.1186/s12935-015-0185-1</pub-id>
<?supplied-pmid 25960691?><pub-id pub-id-type="pmid">25960691</pub-id></element-citation></ref><ref id="B98-ijms-18-00507"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruan</surname><given-names>K.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Ouyang</surname><given-names>G.</given-names></name></person-group>
<article-title>MicroRNAs: Novel regulators in the hallmarks of human cancer</article-title>
<source>Cancer Lett.</source>
<year>2009</year>
<volume>285</volume>
<fpage>116</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2009.04.031</pub-id>
<?supplied-pmid 19464788?><pub-id pub-id-type="pmid">19464788</pub-id></element-citation></ref><ref id="B99-ijms-18-00507"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Leva</surname><given-names>G.</given-names></name><name><surname>Croce</surname><given-names>C.M.</given-names></name></person-group>
<article-title>Roles of small RNAs in tumor formation</article-title>
<source>Trends Mol. Med.</source>
<year>2010</year>
<volume>16</volume>
<fpage>257</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2010.04.001</pub-id>
<?supplied-pmid 20493775?><pub-id pub-id-type="pmid">20493775</pub-id></element-citation></ref><ref id="B100-ijms-18-00507"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Svoronos</surname><given-names>A.A.</given-names></name><name><surname>Engelman</surname><given-names>D.M.</given-names></name><name><surname>Slack</surname><given-names>F.J.</given-names></name></person-group>
<article-title>OncomiR or tumor suppressor? The duplicity of microRNAs in cancer</article-title>
<source>Cancer Res.</source>
<year>2016</year>
<volume>76</volume>
<fpage>3666</fpage>
<lpage>3670</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-0359</pub-id>
<?supplied-pmid 27325641?><pub-id pub-id-type="pmid">27325641</pub-id></element-citation></ref><ref id="B101-ijms-18-00507"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brian</surname><given-names>A.</given-names></name><name><surname>Kasinski</surname><given-names>A.</given-names></name><name><surname>Slack</surname><given-names>F.</given-names></name></person-group>
<article-title>Aberrant regulation and function of microRNAs in cancer</article-title>
<source>Curr. Biol.</source>
<year>2014</year>
<volume>24</volume>
<fpage>762</fpage>
<lpage>776</lpage>
</element-citation></ref><ref id="B102-ijms-18-00507"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>W.</given-names></name></person-group>
<article-title>Serum miRNAs panel (miR-16&#x02013;2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer</article-title>
<source>Sci. Rep.</source>
<year>2015</year>
<volume>14</volume>
<fpage>17942</fpage>
<pub-id pub-id-type="doi">10.1038/srep17942</pub-id>
<?supplied-pmid 26656154?><pub-id pub-id-type="pmid">26656154</pub-id></element-citation></ref><ref id="B103-ijms-18-00507"><label>103.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name><name><surname>Miska</surname><given-names>E.A.</given-names></name><name><surname>Alvarez-Saavedra</surname><given-names>E.</given-names></name><name><surname>Lamb</surname><given-names>J.</given-names></name><name><surname>Peck</surname><given-names>D.</given-names></name><name><surname>Sweet-Cordero</surname><given-names>A.</given-names></name><name><surname>Ebert</surname><given-names>B.L.</given-names></name><name><surname>Mak</surname><given-names>R.H.</given-names></name><name><surname>Ferrando</surname><given-names>A.A.</given-names></name><etal/></person-group>
<article-title>MicroRNA expression profiles classify human cancers</article-title>
<source>Nature</source>
<year>2005</year>
<volume>435</volume>
<fpage>834</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1038/nature03702</pub-id>
<?supplied-pmid 15944708?><pub-id pub-id-type="pmid">15944708</pub-id></element-citation></ref><ref id="B104-ijms-18-00507"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taslim</surname><given-names>C.</given-names></name><name><surname>Weng</surname><given-names>D.Y.</given-names></name><name><surname>Brasky</surname><given-names>T.M.</given-names></name><name><surname>Dumitrescu</surname><given-names>R.G.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Kallakury</surname><given-names>B.V.</given-names></name><name><surname>Krishnan</surname><given-names>S.</given-names></name><name><surname>Llanos</surname><given-names>A.A.</given-names></name><name><surname>Marian</surname><given-names>C.</given-names></name><name><surname>McElroy</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling</article-title>
<source>Oncotarget</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.13241</pub-id>
<?supplied-pmid 27833082?><pub-id pub-id-type="pmid">27833082</pub-id></element-citation></ref><ref id="B105-ijms-18-00507"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iorio</surname><given-names>M.V.</given-names></name><name><surname>Visone</surname><given-names>R.</given-names></name><name><surname>Di Leva</surname><given-names>G.</given-names></name><name><surname>Donati</surname><given-names>V.</given-names></name><name><surname>Petrocca</surname><given-names>F.</given-names></name><name><surname>Casalini</surname><given-names>P.</given-names></name><name><surname>Taccioli</surname><given-names>C.</given-names></name><name><surname>Volinia</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>C.G.</given-names></name><name><surname>Alder</surname><given-names>H.</given-names></name><etal/></person-group>
<article-title>MicroRNA signatures in human ovarian cancer</article-title>
<source>Cancer Res.</source>
<year>2007</year>
<volume>67</volume>
<fpage>8699</fpage>
<lpage>8707</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1936</pub-id>
<?supplied-pmid 17875710?><pub-id pub-id-type="pmid">17875710</pub-id></element-citation></ref><ref id="B106-ijms-18-00507"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lopez</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>S.E.</given-names></name><name><surname>Raz</surname><given-names>D.J.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name></person-group>
<article-title>Circulating miRNA profile in esophageal adenocarcinoma</article-title>
<source>Am. J. Cancer Res.</source>
<year>2016</year>
<volume>6</volume>
<fpage>2713</fpage>
<lpage>2721</lpage>
<?supplied-pmid 27904783?><pub-id pub-id-type="pmid">27904783</pub-id></element-citation></ref><ref id="B107-ijms-18-00507"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shu</surname><given-names>X.</given-names></name><name><surname>Hildebrandt</surname><given-names>M.A.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Tannir</surname><given-names>N.M.</given-names></name><name><surname>Matin</surname><given-names>S.F.</given-names></name><name><surname>Karam</surname><given-names>J.A.</given-names></name><name><surname>Wood</surname><given-names>C.G.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group>
<article-title>MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity</article-title>
<source>Br. J. Cancer</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/bjc.2016.392</pub-id>
<?supplied-pmid 27907930?><pub-id pub-id-type="pmid">27907930</pub-id></element-citation></ref><ref id="B108-ijms-18-00507"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Urquidi</surname><given-names>V.</given-names></name><name><surname>Netherton</surname><given-names>M.</given-names></name><name><surname>Gomes-Giacoia</surname><given-names>E.</given-names></name><name><surname>Serie</surname><given-names>D.J.</given-names></name><name><surname>Eckel-Passow</surname><given-names>J.</given-names></name><name><surname>Rosser</surname><given-names>C.J.</given-names></name><name><surname>Goodison</surname><given-names>S.</given-names></name></person-group>
<article-title>A microRNA biomarker panel for the non-invasive detection of bladder cancer</article-title>
<source>Oncotarget</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.13382</pub-id>
<?supplied-pmid 27863434?><pub-id pub-id-type="pmid">27863434</pub-id></element-citation></ref><ref id="B109-ijms-18-00507"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gadducci</surname><given-names>A.</given-names></name><name><surname>Sergiampietri</surname><given-names>C.</given-names></name><name><surname>Lanfredini</surname><given-names>N.</given-names></name><name><surname>Guiggi</surname><given-names>I.</given-names></name></person-group>
<article-title>Micro-RNAs and ovarian cancer: The state of art and perspectives of clinical research</article-title>
<source>Gynecol. Endocrinol.</source>
<year>2014</year>
<volume>30</volume>
<fpage>266</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.3109/09513590.2013.871525</pub-id>
<?supplied-pmid 24479883?><pub-id pub-id-type="pmid">24479883</pub-id></element-citation></ref><ref id="B110-ijms-18-00507"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pal</surname><given-names>M.K.</given-names></name><name><surname>Jaiswar</surname><given-names>S.P.</given-names></name><name><surname>Dwivedi</surname><given-names>V.N.</given-names></name><name><surname>Tripathi</surname><given-names>A.K.</given-names></name><name><surname>Dwivedi</surname><given-names>A.</given-names></name><name><surname>Sankhwar</surname><given-names>P.</given-names></name></person-group>
<article-title>MicroRNA: A new and promising potential biomarker for diagnosis and prognosis of ovarian cancer</article-title>
<source>Cancer Biol. Med.</source>
<year>2015</year>
<volume>12</volume>
<fpage>328</fpage>
<lpage>341</lpage>
<?supplied-pmid 26779370?><pub-id pub-id-type="pmid">26779370</pub-id></element-citation></ref><ref id="B111-ijms-18-00507"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G.</given-names></name></person-group>
<article-title>Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy</article-title>
<source>Adv. Drug Deliv. Rev.</source>
<year>2015</year>
<volume>81</volume>
<fpage>75</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.addr.2014.09.001</pub-id>
<?supplied-pmid 25220354?><pub-id pub-id-type="pmid">25220354</pub-id></element-citation></ref><ref id="B112-ijms-18-00507"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Unruh</surname><given-names>A.K.</given-names></name><name><surname>Ivan</surname><given-names>C.</given-names></name><name><surname>Baggerly</surname><given-names>K.A.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Bast</surname><given-names>R.C.</given-names><suffix>Jr.</suffix></name><name><surname>Le</surname><given-names>X.F.</given-names></name></person-group>
<article-title>Clinically relevant microRNAs in ovarian cancer</article-title>
<source>Mol. Cancer Res.</source>
<year>2015</year>
<volume>13</volume>
<fpage>393</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0424</pub-id>
<?supplied-pmid 25304686?><pub-id pub-id-type="pmid">25304686</pub-id></element-citation></ref><ref id="B113-ijms-18-00507"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katz</surname><given-names>B.</given-names></name><name><surname>Trop&#x000e9;</surname><given-names>C.G.</given-names></name><name><surname>Reich</surname><given-names>R.</given-names></name><name><surname>Davidson</surname><given-names>B.</given-names></name></person-group>
<article-title>MicroRNAs in ovarian cancer</article-title>
<source>Hum. Pathol.</source>
<year>2015</year>
<volume>46</volume>
<fpage>1245</fpage>
<lpage>1256</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2015.06.013</pub-id>
<?supplied-pmid 26216350?><pub-id pub-id-type="pmid">26216350</pub-id></element-citation></ref><ref id="B114-ijms-18-00507"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kinose</surname><given-names>Y.</given-names></name><name><surname>Sawada</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Kimura</surname><given-names>T.</given-names></name></person-group>
<article-title>The role of microRNAs in ovarian cancer</article-title>
<source>Biomed. Res. Int.</source>
<year>2014</year>
<volume>2014</volume>
<fpage>249393</fpage>
<pub-id pub-id-type="doi">10.1155/2014/249393</pub-id>
<?supplied-pmid 25295252?><pub-id pub-id-type="pmid">25295252</pub-id></element-citation></ref><ref id="B115-ijms-18-00507"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>S.M.</given-names></name><name><surname>Grosshans</surname><given-names>H.</given-names></name><name><surname>Shingara</surname><given-names>J.</given-names></name><name><surname>Byrom</surname><given-names>M.</given-names></name><name><surname>Jarvis</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>A.</given-names></name><name><surname>Labourier</surname><given-names>E.</given-names></name><name><surname>Reinert</surname><given-names>K.L.</given-names></name><name><surname>Brown</surname><given-names>D.</given-names></name><name><surname>Slack</surname><given-names>F.J.</given-names></name></person-group>
<article-title>RAS is regulated by the let-7 microRNA family</article-title>
<source>Cell</source>
<year>2005</year>
<volume>120</volume>
<fpage>635</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2005.01.014</pub-id>
<?supplied-pmid 15766527?><pub-id pub-id-type="pmid">15766527</pub-id></element-citation></ref><ref id="B116-ijms-18-00507"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>J.J.</given-names></name></person-group>
<article-title>HMGA2 and high-grade serous ovarian carcinoma</article-title>
<source>J. Mol. Med.</source>
<year>2013</year>
<volume>91</volume>
<fpage>1155</fpage>
<lpage>1165</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-013-1055-8</pub-id>
<?supplied-pmid 23686260?><pub-id pub-id-type="pmid">23686260</pub-id></element-citation></ref><ref id="B117-ijms-18-00507"><label>117.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Helland</surname><given-names>&#x000c5;.</given-names></name><name><surname>Anglesio</surname><given-names>M.S.</given-names></name><name><surname>George</surname><given-names>J.</given-names></name><name><surname>Cowin</surname><given-names>P.A.</given-names></name><name><surname>Johnstone</surname><given-names>C.N.</given-names></name><name><surname>House</surname><given-names>C.M.</given-names></name><name><surname>Sheppard</surname><given-names>K.E.</given-names></name><name><surname>Etemadmoghadam</surname><given-names>D.</given-names></name><name><surname>Melnyk</surname><given-names>N.</given-names></name><name><surname>Rustgi</surname><given-names>A.K.</given-names></name><etal/></person-group>
<article-title>Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers</article-title>
<source>PLoS ONE</source>
<year>2011</year>
<volume>6</volume>
<elocation-id>e18064</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0018064</pub-id>
<?supplied-pmid 21533284?><pub-id pub-id-type="pmid">21533284</pub-id></element-citation></ref><ref id="B118-ijms-18-00507"><label>118.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Hao</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name></person-group>
<article-title>Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<elocation-id>e77853</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0077853</pub-id>
<?supplied-pmid 24223734?><pub-id pub-id-type="pmid">24223734</pub-id></element-citation></ref><ref id="B119-ijms-18-00507"><label>119.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group>
<article-title>MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2</article-title>
<source>Gynecol. Oncol.</source>
<year>2011</year>
<volume>122</volume>
<fpage>149</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2011.03.026</pub-id>
<?supplied-pmid 21529905?><pub-id pub-id-type="pmid">21529905</pub-id></element-citation></ref><ref id="B120-ijms-18-00507"><label>120.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Jaarsveld</surname><given-names>M.T.</given-names></name><name><surname>Helleman</surname><given-names>J.</given-names></name><name><surname>Boersma</surname><given-names>A.W.</given-names></name><name><surname>van Kuijk</surname><given-names>P.F.</given-names></name><name><surname>van Ijcken</surname><given-names>W.F.</given-names></name><name><surname>Despierre</surname><given-names>E.</given-names></name><name><surname>Vergote</surname><given-names>I.</given-names></name><name><surname>Mathijssen</surname><given-names>R.H.</given-names></name><name><surname>Berns</surname><given-names>E.M.</given-names></name><name><surname>Verweij</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells</article-title>
<source>Oncogene</source>
<year>2013</year>
<volume>32</volume>
<fpage>4284</fpage>
<lpage>4293</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2012.433</pub-id>
<?supplied-pmid 23045278?><pub-id pub-id-type="pmid">23045278</pub-id></element-citation></ref><ref id="B121-ijms-18-00507"><label>121.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cochrane</surname><given-names>D.R.</given-names></name><name><surname>Spoelstra</surname><given-names>N.S.</given-names></name><name><surname>Howe</surname><given-names>E.N.</given-names></name><name><surname>Nordeen</surname><given-names>S.K.</given-names></name><name><surname>Richer</surname><given-names>J.K.</given-names></name></person-group>
<article-title>MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents</article-title>
<source>Mol. Cancer Ther.</source>
<year>2009</year>
<volume>8</volume>
<fpage>1055</fpage>
<lpage>1066</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-1046</pub-id>
<?supplied-pmid 19435871?><pub-id pub-id-type="pmid">19435871</pub-id></element-citation></ref><ref id="B122-ijms-18-00507"><label>122.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cittelly</surname><given-names>D.M.</given-names></name><name><surname>Dimitrova</surname><given-names>I.</given-names></name><name><surname>Howe</surname><given-names>E.N.</given-names></name><name><surname>Cochrane</surname><given-names>D.R.</given-names></name><name><surname>Jean</surname><given-names>A.</given-names></name><name><surname>Spoelstra</surname><given-names>N.S.</given-names></name><name><surname>Post</surname><given-names>M.D.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Broaddus</surname><given-names>R.R.</given-names></name><name><surname>Spillman</surname><given-names>M.A.</given-names></name><etal/></person-group>
<article-title>Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel</article-title>
<source>Mol. Cancer Ther.</source>
<year>2012</year>
<volume>11</volume>
<fpage>2556</fpage>
<lpage>2565</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0463</pub-id>
<?supplied-pmid 23074172?><pub-id pub-id-type="pmid">23074172</pub-id></element-citation></ref><ref id="B123-ijms-18-00507"><label>123.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Greshock</surname><given-names>J.</given-names></name><name><surname>Megraw</surname><given-names>M.S.</given-names></name><name><surname>Giannakakis</surname><given-names>A.</given-names></name><name><surname>Liang</surname><given-names>S.</given-names></name><name><surname>Naylor</surname><given-names>T.L.</given-names></name><name><surname>Barchetti</surname><given-names>A.</given-names></name><name><surname>Ward</surname><given-names>M.R.</given-names></name><etal/></person-group>
<article-title>microRNAs exhibit high frecuency genomic alteration in human cancer</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2006</year>
<volume>103</volume>
<fpage>9136</fpage>
<lpage>9141</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0508889103</pub-id>
<?supplied-pmid 16754881?><pub-id pub-id-type="pmid">16754881</pub-id></element-citation></ref><ref id="B124-ijms-18-00507"><label>124.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Italiano</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>R.</given-names></name><name><surname>Breen</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Crago</surname><given-names>A.M.</given-names></name><name><surname>Singer</surname><given-names>S.</given-names></name><name><surname>Khanin</surname><given-names>R.</given-names></name><name><surname>Maki</surname><given-names>R.G.</given-names></name><name><surname>Mihailovic</surname><given-names>A.</given-names></name><name><surname>Hafner</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>The miR-17&#x02013;92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification</article-title>
<source>Genes Chromosomes Cancer</source>
<year>2012</year>
<volume>51</volume>
<fpage>569</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.21943</pub-id>
<?supplied-pmid 22383169?><pub-id pub-id-type="pmid">22383169</pub-id></element-citation></ref><ref id="B125-ijms-18-00507"><label>125.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lou</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Cui</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name></person-group>
<article-title>MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein</article-title>
<source>Int. J. Mol. Med.</source>
<year>2010</year>
<volume>26</volume>
<fpage>819</fpage>
<lpage>827</lpage>
<pub-id pub-id-type="doi">10.3892/ijmm_00000530</pub-id>
<?supplied-pmid 21042775?><pub-id pub-id-type="pmid">21042775</pub-id></element-citation></ref><ref id="B126-ijms-18-00507"><label>126.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cappellesso</surname><given-names>R.</given-names></name><name><surname>Tinazzi</surname><given-names>A.</given-names></name><name><surname>Giurici</surname><given-names>T.</given-names></name><name><surname>Simonato</surname><given-names>F.</given-names></name><name><surname>Guzzardo</surname><given-names>V.</given-names></name><name><surname>Ventura</surname><given-names>L.</given-names></name><name><surname>Crescenzi</surname><given-names>M.</given-names></name><name><surname>Chiarelli</surname><given-names>S.</given-names></name><name><surname>Fassina</surname><given-names>A.</given-names></name></person-group>
<article-title>Programmed cell death 4 and miR-21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions</article-title>
<source>Cancer Cytopathol.</source>
<year>2014</year>
<volume>122</volume>
<fpage>685</fpage>
<lpage>693</lpage>
<pub-id pub-id-type="doi">10.1002/cncy.21442</pub-id>
<?supplied-pmid 24888238?><pub-id pub-id-type="pmid">24888238</pub-id></element-citation></ref><ref id="B127-ijms-18-00507"><label>127.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>B&#x000e1;ez-Vega</surname><given-names>P.M.</given-names></name><name><surname>Echevarr&#x000ed;a Vargas</surname><given-names>I.M.</given-names></name><name><surname>Valiyeva</surname><given-names>F.</given-names></name><name><surname>Encarnaci&#x000f3;n-Rosado</surname><given-names>J.</given-names></name><name><surname>Roman</surname><given-names>A.</given-names></name><name><surname>Flores</surname><given-names>J.</given-names></name><name><surname>Marcos-Mart&#x000ed;nez</surname><given-names>M.J.</given-names></name><name><surname>Vivas-Mej&#x000ed;a</surname><given-names>P.E.</given-names></name></person-group>
<article-title>Targeting miR-21&#x02013;3p inhibits proliferation and invasion of ovarian cancer cells</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<fpage>36321</fpage>
<lpage>36337</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.9216</pub-id>
<?supplied-pmid 27166999?><pub-id pub-id-type="pmid">27166999</pub-id></element-citation></ref><ref id="B128-ijms-18-00507"><label>128.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.Z.</given-names></name><name><surname>Xi</surname><given-names>Q.H.</given-names></name><name><surname>Ge</surname><given-names>W.L.</given-names></name><name><surname>Zhang</surname><given-names>X.Q.</given-names></name></person-group>
<article-title>Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer</article-title>
<source>Asian Pac. J. Cancer Prev.</source>
<year>2013</year>
<volume>14</volume>
<fpage>1057</fpage>
<lpage>1060</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2013.14.2.1057</pub-id>
<?supplied-pmid 23621186?><pub-id pub-id-type="pmid">23621186</pub-id></element-citation></ref><ref id="B129-ijms-18-00507"><label>129.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kent</surname><given-names>O.A.</given-names></name><name><surname>McCall</surname><given-names>M.N.</given-names></name><name><surname>Cornish</surname><given-names>T.C.</given-names></name><name><surname>Halushka</surname><given-names>M.K.</given-names></name></person-group>
<article-title>Lessons from miR-143/145: The importance of cell-type localization of miRNAs</article-title>
<source>Nucleic Acids Res.</source>
<year>2014</year>
<volume>42</volume>
<fpage>7528</fpage>
<lpage>7538</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku461</pub-id>
<?supplied-pmid 24875473?><pub-id pub-id-type="pmid">24875473</pub-id></element-citation></ref><ref id="B130-ijms-18-00507"><label>130.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>L.Z.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Lai</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>B.H.</given-names></name></person-group>
<article-title>MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth angiogenesis</article-title>
<source>Nucleic Acids Res.</source>
<year>2012</year>
<volume>40</volume>
<fpage>761</fpage>
<lpage>774</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkr730</pub-id>
<?supplied-pmid 21917858?><pub-id pub-id-type="pmid">21917858</pub-id></element-citation></ref><ref id="B131-ijms-18-00507"><label>131.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group>
<article-title>MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer</article-title>
<source>Technol. Cancer Res. Treat.</source>
<year>2014</year>
<volume>13</volume>
<fpage>161</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.7785/tcrt.2012.500367</pub-id>
<?supplied-pmid 23919393?><pub-id pub-id-type="pmid">23919393</pub-id></element-citation></ref><ref id="B132-ijms-18-00507"><label>132.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mataki</surname><given-names>H.</given-names></name><name><surname>Seki</surname><given-names>N.</given-names></name><name><surname>Mizuno</surname><given-names>K.</given-names></name><name><surname>Nohata</surname><given-names>N.</given-names></name><name><surname>Kamikawaji</surname><given-names>K.</given-names></name><name><surname>Kumamoto</surname><given-names>T.</given-names></name><name><surname>Koshizuka</surname><given-names>K.</given-names></name><name><surname>Goto</surname><given-names>Y.</given-names></name><name><surname>Inoue</surname><given-names>H.</given-names></name></person-group>
<article-title>Dual-strand tumor-suppressor microRNA-145 (miR-145&#x02013;5p and miR-145&#x02013;3p) coordinately targeted MTDH in lung squamous cell carcinoma</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<fpage>72085</fpage>
<lpage>72098</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.12290</pub-id>
<?supplied-pmid 27765924?><pub-id pub-id-type="pmid">27765924</pub-id></element-citation></ref><ref id="B133-ijms-18-00507"><label>133.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>J.Y.</given-names></name><name><surname>Meng</surname><given-names>X.N.</given-names></name><name><surname>Xiu</surname><given-names>Y.L.</given-names></name><name><surname>Zong</surname><given-names>Z.H.</given-names></name></person-group>
<article-title>MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression</article-title>
<source>J. Exp. Clin. Cancer Res.</source>
<year>2016</year>
<volume>35</volume>
<fpage>31</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-016-0307-1</pub-id>
<?supplied-pmid 26872615?><pub-id pub-id-type="pmid">26872615</pub-id></element-citation></ref><ref id="B134-ijms-18-00507"><label>134.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name></person-group>
<article-title>MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2</article-title>
<source>FEBS Lett.</source>
<year>2014</year>
<volume>588</volume>
<fpage>1608</fpage>
<lpage>1615</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2014.02.055</pub-id>
<?supplied-pmid 24613919?><pub-id pub-id-type="pmid">24613919</pub-id></element-citation></ref><ref id="B135-ijms-18-00507"><label>135.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Ge</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group>
<article-title>Up-regulation of miR-204 enhaces anoikis sensitivity in ephitehlial ovarian cancer cell line via brain-derived neurotrophic factor pathway in vitro</article-title>
<source>Int. J. Gynecol. Cancer</source>
<year>2015</year>
<volume>25</volume>
<fpage>944</fpage>
<lpage>952</lpage>
<pub-id pub-id-type="doi">10.1097/IGC.0000000000000456</pub-id>
<?supplied-pmid 25962115?><pub-id pub-id-type="pmid">25962115</pub-id></element-citation></ref><ref id="B136-ijms-18-00507"><label>136.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montalban</surname><given-names>E.</given-names></name><name><surname>Mattugini</surname><given-names>N.</given-names></name><name><surname>Ciarapica</surname><given-names>R.</given-names></name><name><surname>Provenzano</surname><given-names>C.</given-names></name><name><surname>Savino</surname><given-names>M.</given-names></name><name><surname>Scagnoli</surname><given-names>F.</given-names></name><name><surname>Prosperini</surname><given-names>G.</given-names></name><name><surname>Carissimi</surname><given-names>C.</given-names></name><name><surname>Fulci</surname><given-names>V.</given-names></name><name><surname>Matrone</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>MiR-21 is an NGF-modulated microRNA that supports NGF signaling and regulates neuronal degeneration in PC12 cells</article-title>
<source>Neuromol. Med.</source>
<year>2014</year>
<volume>16</volume>
<fpage>415</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="doi">10.1007/s12017-014-8292-z</pub-id>
<?supplied-pmid 24492999?><pub-id pub-id-type="pmid">24492999</pub-id></element-citation></ref><ref id="B137-ijms-18-00507"><label>137.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kashyap</surname><given-names>M.</given-names></name><name><surname>Pore</surname><given-names>S.</given-names></name><name><surname>Chancellor</surname><given-names>M.</given-names></name><name><surname>Yoshimura</surname><given-names>N.</given-names></name><name><surname>Tyagi</surname><given-names>P.</given-names></name></person-group>
<article-title>Bladder overactivity involves overexpression of microRNA 132 and nerve growth factor</article-title>
<source>Life Sci.</source>
<year>2016</year>
<volume>167</volume>
<fpage>98</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2016.10.025</pub-id>
<?supplied-pmid 27789288?><pub-id pub-id-type="pmid">27789288</pub-id></element-citation></ref><ref id="B138-ijms-18-00507"><label>138.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Othumpangat</surname><given-names>S.</given-names></name><name><surname>Walton</surname><given-names>C.</given-names></name><name><surname>Piedimonte</surname><given-names>G.</given-names></name></person-group>
<article-title>MicroRNA-221 modulates RSV replication in human bronchial epithelial by targeting NGF expression</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>e30030</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0030030</pub-id>
<?supplied-pmid 22272270?><pub-id pub-id-type="pmid">22272270</pub-id></element-citation></ref><ref id="B139-ijms-18-00507"><label>139.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name><name><surname>Nuovo</surname><given-names>G.</given-names></name><name><surname>Ramaswamy</surname><given-names>B.</given-names></name><name><surname>Miller</surname><given-names>T.</given-names></name><name><surname>Shapiro</surname><given-names>C.</given-names></name><name><surname>Jacob</surname><given-names>S.T.</given-names></name><name><surname>Majumder</surname><given-names>S.</given-names></name></person-group>
<article-title>Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamixofen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal</article-title>
<source>J. Biol. Chem.</source>
<year>2011</year>
<volume>286</volume>
<fpage>42292</fpage>
<lpage>42302</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.270926</pub-id>
<?supplied-pmid 22009755?><pub-id pub-id-type="pmid">22009755</pub-id></element-citation></ref><ref id="B140-ijms-18-00507"><label>140.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.L.</given-names></name><name><surname>Cheng</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>P.Y.</given-names></name><name><surname>Huang</surname><given-names>H.J.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Dan</surname><given-names>Z.L.</given-names></name><name><surname>Tian</surname><given-names>D.A.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name></person-group>
<article-title>MicroRNA-143 suppresses gastric cancer cells growth and induces apoptosis by targeting COX2</article-title>
<source>World J. Gastroenterol.</source>
<year>2013</year>
<volume>19</volume>
<fpage>7758</fpage>
<lpage>7765</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v19.i43.7758</pub-id>
<?supplied-pmid 24616567?><pub-id pub-id-type="pmid">24616567</pub-id></element-citation></ref><ref id="B141-ijms-18-00507"><label>141.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name></person-group>
<article-title>MiR-143 targets CTCF and exerts tumor-suppressing functions in epithelial ovarian cancer</article-title>
<source>Am. J. Transl. Res.</source>
<year>2016</year>
<volume>8</volume>
<fpage>2716</fpage>
<lpage>2726</lpage>
<?supplied-pmid 27398154?><pub-id pub-id-type="pmid">27398154</pub-id></element-citation></ref><ref id="B142-ijms-18-00507"><label>142.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manek</surname><given-names>R.</given-names></name><name><surname>Pakzamir</surname><given-names>E.</given-names></name><name><surname>Mhawech-Fauceglia</surname><given-names>P.</given-names></name><name><surname>Pejovic</surname><given-names>T.</given-names></name><name><surname>Sowter</surname><given-names>H.</given-names></name><name><surname>Gayther</surname><given-names>S.A.</given-names></name><name><surname>Lawrenson</surname><given-names>K.</given-names></name></person-group>
<article-title>Targeting SRC in endometriosis-associated ovarian cancer</article-title>
<source>Oncogenesis</source>
<year>2016</year>
<volume>5</volume>
<fpage>e251</fpage>
<pub-id pub-id-type="doi">10.1038/oncsis.2016.54</pub-id>
<?supplied-pmid 27526105?><pub-id pub-id-type="pmid">27526105</pub-id></element-citation></ref><ref id="B143-ijms-18-00507"><label>143.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Z.K.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name></person-group>
<article-title>Integrity of SOS1/EPS8/ABI1 TRI-complex determines ovarian cancer metastasis</article-title>
<source>Cancer Res.</source>
<year>2016</year>
<volume>70</volume>
<fpage>9979</fpage>
<lpage>9990</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2394</pub-id>
<?supplied-pmid 21118970?><pub-id pub-id-type="pmid">21118970</pub-id></element-citation></ref><ref id="B144-ijms-18-00507"><label>144.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fulciniti</surname><given-names>M.</given-names></name><name><surname>Amodio</surname><given-names>N.</given-names></name><name><surname>Bandi</surname><given-names>R.L.</given-names></name><name><surname>Cagnetta</surname><given-names>A.</given-names></name><name><surname>Samur</surname><given-names>M.K.</given-names></name><name><surname>Acharya</surname><given-names>C.</given-names></name><name><surname>Prabhala</surname><given-names>R.</given-names></name><name><surname>D&#x02019;Aquila</surname><given-names>P.</given-names></name><name><surname>Bellizzi</surname><given-names>D.</given-names></name><name><surname>Passarino</surname><given-names>G.</given-names></name></person-group>
<article-title>miR-23b/SP1/c-Myc forms a feed-forward loop supporting multiple myeloma cell growth</article-title>
<source>Blood Cancer J.</source>
<year>2016</year>
<volume>15</volume>
<fpage>e380</fpage>
<pub-id pub-id-type="doi">10.1038/bcj.2015.106</pub-id>
<?supplied-pmid 26771806?><pub-id pub-id-type="pmid">26771806</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-18-00507-f001" position="float"><label>Figure 1</label><caption><p>Nerve growth factor (NGF) and its Tyrosine Kinase A receptor (TRKA) are involved in several signaling pathways in epithelial ovarian cancer (EOC). Ovarian cancer cells express and secrete NGF. Through TRKA activation, NGF induces angiogenesis by directly stimulating endothelial cell proliferation and migration. NGF also regulates angiogenesis in an indirect manner through vascular endothelial growth factor (VEGF) production by epithelial cancer cells. This mechanism involves TRKA activation and the Mitogen-activated protein kinase/Extracellular signal-regulated kinase (MEK/ERK) signaling pathway. Besides, NGF increases ciclooxigenase-2 (COX-2) levels, a proinflamatory molecule that induces protaglandine-2 (PGE-2) production; COX-2 and PGE-2 have been associated with invasion in cancer cells. NGF can also increase calreticulin (CRT) levels (Red Arrow), an endoplasmic reticulum resident whose levels have been found to be elevated in several cancers, where it participates in cell survival and invasion. Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a proteinase, also seems to be regulated by NGF-TRKA activation. ADAM17 cleaves the p75 receptor, which is then cleaved a second time by &#x003b3;-secretase. The biological effects of these cuts remain unknown. ADAM 17 can also cleave TRKA, leaving its intracellular domain active, which contributes to cancer progression through the MAPKs and PI3K/Akt pathways.</p></caption><graphic xlink:href="ijms-18-00507-g001"/></fig><fig id="ijms-18-00507-f002" position="float"><label>Figure 2</label><caption><p>MicroRNA (miR) expression is altered in a cancer cell. A normal cell has equilibrium between oncomiRs (overexpressed miRs in cancer) and tumor suppressor miRs (downregulated miRs in cancer), This equibrium is lost in a cancer cells (yellow arrow). This is reflected on mRNA expression, rising oncogenic and decreasing tumor suppressor mRNA levels, and allowing for cancer development.</p></caption><graphic xlink:href="ijms-18-00507-g002"/></fig><fig id="ijms-18-00507-f003" position="float"><label>Figure 3</label><caption><p>miR-23b levels in epithelial ovarian cancer and its relationship with NGF in cell lines. (<bold>A</bold>) miR-23b levels in tissues from inactive ovary (I-Ov), tumor and EOC samples. miR-23b levels from tumor and EOC samples are significantly lower than I-Ov (** = <italic>p</italic> &#x0003c; 0.01); (<bold>B</bold>) miR-23b basal level comparision between HOSE and A2780 cell lines (* = <italic>p</italic> &#x0003c; 0.05); (<bold>C</bold>) NGF effect on miR-23b levels in HOSE cell line. NGF reduces miR-23b levels respect to basal condition (* = <italic>p</italic> &#x0003c; 0.05); (<bold>D</bold>) NGF effect on miR-23b levels in A2780 cell line. NGF reduces miR-23b levels respect to basal condition (* = <italic>p</italic> &#x0003c; 0.05). Stadistic: Kruskal&#x02013;Wallis Test: <bold>A</bold>; Mann&#x02013;Whitney Test: <bold>B</bold>, <bold>C</bold> and <bold>D</bold>.</p></caption><graphic xlink:href="ijms-18-00507-g003"/></fig><fig id="ijms-18-00507-f004" position="float"><label>Figure 4</label><caption><p>NGF and miRs in epithelial ovarian cancer. NGF binds to its high affinity receptor TRKA, activating MAPK and PI3K/AKT signaling pathways. Deregulation in miR expression has been reported in EOC, and NGF could regulate primary-miR (pri-MiR) synthesis. RNApol II/III synthesizes miRs, and afterwards proteins cleave both pri-miR and precursor miRs (pre-miR), in the nucleus and in the cytoplasm, respectively, leading to miR maturation. mRNA repression is done by RNA-silencing inducing complex (RISC), a multiprotein complex, and by the mature miR, regulating mRNA expression through its degradation, deadenilation or inhibiting its translation. Therefore, we hypothesized that NGF/TRKA modifies miR expression in order to regulate VEGF, COX2 and ADAM17 protein levels. An increase of VEGF, COX2 and ADAM17 are related with changes in angiogenesis, migration and proliferation, processes needed for EOC development.</p></caption><graphic xlink:href="ijms-18-00507-g004"/></fig><table-wrap id="ijms-18-00507-t001" position="float"><object-id pub-id-type="pii">ijms-18-00507-t001_Table 1</object-id><label>Table 1</label><caption><p>miR-23b validated targets from miRWalk 2.0.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">miR-23b EOC-Related Targets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">miR-23b NGF-Related Targets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">miR-23b EOC and NGF Related Targets</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NOTCH 1</td><td align="center" valign="middle" rowspan="1" colspan="1">VAV3</td><td align="center" valign="middle" rowspan="1" colspan="1">SRC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HMGB2</td><td align="center" valign="middle" rowspan="1" colspan="1">KLF10</td><td align="center" valign="middle" rowspan="1" colspan="1">SOS1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ZEB1</td><td align="center" valign="middle" rowspan="1" colspan="1">SOCS6</td><td align="center" valign="middle" rowspan="1" colspan="1">SOD1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VCAM1</td><td align="center" valign="middle" rowspan="1" colspan="1">NOTCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">PTEN</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RB1</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap></floats-group></article>